312 results on '"Robison, Leslie L"'
Search Results
2. Estimating the Burden of Recurrent Events in the Presence of Competing Risks: The Method of Mean Cumulative Count.
- Author
-
Huiru Dong, Robison, Leslie L., Leisenring, Wendy M., Martin, Leah J., Armstrong, Gregory T., and Yasui, Yutaka
- Subjects
- *
ECONOMIC aspects of diseases , *RESEARCH funding , *TIME , *DISEASE relapse , *GUTTMAN scale - Abstract
Cumulative incidence has been widely used to estimate the cumulative probability of developing an event of interest by a given time, in the presence of competing risks. When it is of interest to measure the total burden of recurrent events in a population, however, the cumulative incidence method is not appropriate because it considers only the first occurrence of the event of interest for each individual in the analysis: Subsequent occurrences are not included. Here, we discuss a straightforward and intuitive method termed "mean cumulative count," which reflects a summarization of all events that occur in the population by a given time, not just the first event for each subject.We explore the mathematical relationship between mean cumulative count and cumulative incidence. Detailed calculation of mean cumulative count is described by using a simple hypothetical example, and the computation code with an illustrative example is provided. Using follow-up data from January 1975 to August 2009 collected in the Childhood Cancer Survivor Study, we show applications of mean cumulative count and cumulative incidence for the outcome of subsequent neoplasms to demonstrate different but complementary information obtained from the 2 approaches and the specific utility of the former. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Impact of Cancer Therapy-RelatedExposures on LateMortality in Childhood Cancer Survivors.
- Author
-
Gibson, Todd M. and Robison, Leslie L.
- Subjects
- *
CHILDHOOD cancer , *CANCER chemotherapy , *CARDIOVASCULAR diseases , *CANCER treatment , *ETIOLOGY of diseases , *PHYSIOLOGICAL effects of radiation , *DIAGNOSIS - Abstract
Survivalof children and adolescents diagnosed with cancer hasimproved dramatically in recent decades, but the substantial burdenof late morbidity and mortality (i.e., more than 5 years after cancerdiagnosis) associated with pediatric cancer treatments is increasinglybeing recognized. Progression or recurrence of the initial canceris a primary cause of death in the initial postdiagnosis period, butas survivors age, there is a dramatic shift in the cause-specificmortality profile. By 15 years postdiagnosis, the death rate attributableto health-related causes other than recurrence or external causes(e.g., accidents, suicide, assault) exceeds that due to primary disease,and by 30 years, these causes account for the largest proportion ofcumulative mortality. The two most prominent causes of treatment-relatedmortality in childhood cancer survivors are subsequent malignant neoplasmsand cardiovascular problems, the incidence of which can be largelyattributed to the long-term toxicities of radiation and chemotherapyexposures. These late effects of treatment are likely to increasein importance as survivors continue to age, inspiring continued researchto better understand their etiology and to inform early detectionor prevention efforts. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Survivors of childhood and adolescent cancer: life-long risks and responsibilities.
- Author
-
Robison, Leslie L. and Hudson, Melissa M.
- Subjects
- *
CHILDHOOD cancer , *HEALTH outcome assessment , *CANCER patients , *MORTALITY , *DIAGNOSIS ,DEVELOPED countries - Abstract
Survival rates for most paediatric cancers have improved at a remarkable pace over the past four decades. In developed countries, cure is now the probable outcome for most children and adolescents who are diagnosed with cancer: their 5-year survival rate approaches 80%. However, the vast majority of these cancer survivors will have at least one chronic health condition by 40 years of age. The burden of responsibility to understand the long-term morbidity and mortality that is associated with currently successful treatments must be borne by many, including the research and health care communities, survivor advocacy groups, and governmental and policy-making entities. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Opportunities and challenges of establishing a nationwide strategy for adolescents and young adults in Canada with cancer.
- Author
-
Robison, Leslie L.
- Subjects
- *
CANCER patients , *CANCER treatment , *DISEASES in young adults , *HEALTH promotion , *ADULT education workshops - Abstract
Currently, there is priority to address the complex needs of the adolescent and young adult (AYA) cancer population. At a workshop in Toronto, the Canadian healthcare community brought together a broad range of stakeholders to discuss the opportunities and challenges of developing a nationwide strategy for AYA cancer patients. Summarized here is an overview of the workshop objectives and considerations coming from the conference participants relative to opportunities, challenges, and future directions. It is concluded that the Canadian healthcare and advocacy communities are well-positioned to have a major impact and assume a leadership role in AYA cancer care. Cancer 2011;117(10 suppl):2351-4. © 2011 American Cancer Society.. A workshop was convened to identify the opportunities and challenges associated with developing and implementing a nationwide strategy for the diagnosis, treatment, and follow-up of adolescents and young adults (AYA) with cancer. The Canadian healthcare and advocacy communities were well-positioned to have a major impact and assume a leadership role in AYA cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. Acute lymphoblastic leukaemia.
- Author
-
Ching-Hon Pui, Robison, Leslie L., and Look, A. Thomas
- Subjects
- *
LYMPHOBLASTIC leukemia treatment , *LYMPHOCYTIC leukemia , *CHILDHOOD cancer , *NANOTECHNOLOGY , *ETIOLOGY of diseases , *EPIDEMIOLOGICAL research - Abstract
The article presents an overview of acute lymphoblastic leukemia, a malignant disorder of lymphoid progenitor cells which affects both children and adults and affects children prevalently between the ages of two and five years of age. A discussion of research associated with emerging molecular technologies which may help physicians understand the pathobiology of acute lymphoblastic leukemia is presented. The epidemiology, cause, pathobiology, management and treatment of the disease is discussed.
- Published
- 2008
- Full Text
- View/download PDF
7. New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study.
- Author
-
Neglia, Joseph P., Robison, Leslie L., Stovall, Marilyn, Yan Liu, Packer, Roger J., Hammond, Sue, Yasui, Yutaka, Kasper, Catherine E., Mertens, Ann C., Donaldson, Sarah S., Meadows, Anna T., and Inskip, Peter D.
- Subjects
- *
TUMORS , *CENTRAL nervous system , *CHILDREN of cancer patients , *MEDICAL records , *RADIOTHERAPY , *THERAPEUTICS - Abstract
Background: Subsequent primary neoplasms of the central nervous system (CNS) have frequently been described as late events following childhood leukemia and brain tumors. However, the details of the dose-response relationships, the expression of excess risk over time, and the modifying effects of other host and treatment factors have not been well defined. Methods: Subsequent primary neoplasms of the CNS occurring within a cohort of 14361 5-year survivors of childhood cancers were ascertained. Each patient was matched with four control subjects by age, sex, and time since original cancer diagnosis. Tumor site-specific radiation dosimetry was performed, and chemotherapy information was abstracted from medical records. Conditional logistic regression was used to estimate odds ratios (ORs), to calculate 95% confidence intervals (Cis), and to model the excess relative risk (ERR) as a function of radiation dose and host factors. For subsequent gliomas, standardized incidence ratios (SIRs) and excess absolute risks (EARs) were calculated based on Surveillance, Epidemiology, and End Results data. Results: Subsequent CNS primary neoplasms were identified in 116 individuals. Gliomas (n = 40) occurred a median of 9 years from original diagnosis; for meningiomas (n = 66), it was 17 years. Radiation exposure was associated with increased risk of subsequent glioma (OR = 6.78, 95% CI = 1.54 to 29.7) and meningioma (OR = 9.94, 95% Cl = 2.17 to 45.6). The dose response for the excess relative risk was linear (for glioma, slope = 0.33 195% CI = 0.07 to 1.711 per Gy, and for meningioma, slope = 1.06 [95% CI = 0.21 to 8.15] per Gy). For glioma, the ERR/Gy was highest among children exposed at less than 5 years of age. After adjustment for radiation dose, neither original cancer diagnosis nor chemotherapy was associated with risk. The overall SIR for glioma was 8.7, and the EAR was 19.3 per 10 000 person-years. Conclusions: Exposure to radiation therapy is the most important risk factor for the development of a new CNS tumor in survivors of childhood cancers. The higher risk of subsequent glioma in children irradiated at a very young age may reflect greater susceptibility of the developing brain to radiation. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.
- Author
-
Robison, Leslie L. and Bhatia, Smita
- Subjects
- *
LEUKEMIA in children , *LYMPHOMAS , *STEM cell transplantation , *BEHAVIORAL toxicology , *LEUKEMIA treatment - Abstract
With improvements in survival rates for children and adolescents diagnosed with leukaemia or lymphoma, issues relating to late treatment-related sequelae have increased in importance. This article reviews late adverse outcomes, including second malignancies, cardiotoxicity, endocrinological effects, impact on neurocognitive neuropsychological status, late mortality and implications of stem cell transplantation. As treatment- and patient-related factors impact the subsequent risk of late occurring adverse outcomes, clear delineation of those leukaemia and lymphoma survivors who are at high risk of specific adverse outcomes is essential for the rational design of follow-up guidelines, prevention and intervention strategies.
- Published
- 2003
- Full Text
- View/download PDF
9. Childhood Cancer Survivors' Knowledge About Their Past Diagnosis and Treatment: Childhood Cancer Survivor Study.
- Author
-
Kadan-Lottick, Nina S., Robison, Leslie L., Gurney, James G., Neglia, Joseph P., Yasui, Yutaka, Hayashi, Robert, Hudson, Melissa, Greenberg, Mark, and Mertens, Ann C.
- Subjects
- *
CHILDHOOD cancer , *CANCER patients , *DIAGNOSIS , *THERAPEUTICS - Abstract
Context: Adult survivors of childhood cancer are at risk for adverse effects later in life but may have limited access to information about their diagnosis and treatment. This knowledge is necessary to motivate them to seek medical follow-up and to report essential history to health care professionals. Objective: To assess knowledge of adult survivors of childhood cancer about their primary cancer diagnosis and associated therapies. Design, Setting, and Participants: Cross-sectional survey of 635 consecutive survivors (approximately 5%) drawn from 12 156 participants 18 years or older participating in the Childhood Cancer Survivor Study (a multiinstitutional cohort of individuals diagnosed between January 1, 1970, and December 31,1986, at an age <21 years, who had survived 5 years from diagnosis).The survey assessed knowledge of their cancer diagnosis and associated therapies in a 3- to 5-minute telephone questionnaire. Main Outcome Measures: Responses were compared with medical record data for accuracy, sensitivity, specificity, and positive and negative predictive value. Results: Overall, 72% accurately reported their diagnosis with precision and 19% were accurate but not precise. Individuals with central nervous system (CNS) cancer (odds ratio, 5.1; 95% confidence interval, 2.6-9.9) and neuroblastoma (OR, 4.2; 95% CI, 1.8-9.6) were more likely not to know their cancer diagnosis. Participants' accuracy rates for reporting their treatment history was 94% for chemotherapy, 89% for radiation, and 93% for splenectomy. Among those who received anthracyclines, only 30% recalled receiving daunorubicin therapy and 52% recalled receiving doxorubicin therapy, even after prompting with the drugs' names. Among those who received radiotherapy, 70% recalled the site of radiotherapy. History of receiving a written medical summary, attending a long-term follow-up clinic, and anxiety about late effects were not associated with greater knowledge. Conclusions: Important... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
10. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
- Author
-
Friedman, Danielle Novetsky, Goodman, Pamela J, Leisenring, Wendy M, Diller, Lisa R, Cohn, Susan L, Howell, Rebecca M, Smith, Susan A, Tonorezos, Emily S, Wolden, Suzanne L, Neglia, Joseph P, Ness, Kirsten K, Gibson, Todd M, Nathan, Paul C, Turcotte, Lucie M, Weil, Brent R, Robison, Leslie L, Oeffinger, Kevin C, Armstrong, Gregory T, Sklar, Charles A, and Henderson, Tara O
- Subjects
- *
NEUROBLASTOMA , *CHILDHOOD cancer , *CANCER survivors , *STEM cell transplantation , *MORTALITY , *REGRESSION analysis - Abstract
Background Early efforts at risk-adapted therapy for neuroblastoma are predicted to result in differential late effects; the magnitude of these differences has not been well described. Methods Late mortality, subsequent malignant neoplasms (SMNs), and severe/life-threatening chronic health conditions (CHCs), graded according to CTCAE v4.03, were assessed among 5-year Childhood Cancer Survivor Study (CCSS) survivors of neuroblastoma diagnosed 1987-1999. Using age, stage at diagnosis, and treatment, survivors were classified into risk groups (low [n = 425]; intermediate [n = 252]; high [n = 245]). Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) of SMNs were compared with matched population controls. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals for CHC compared with 1029 CCSS siblings. Results Among survivors (49.8% male; median age = 21 years, range = 7-42; median follow-up = 19.3 years, range = 5-29.9), 80% with low-risk disease were treated with surgery alone, whereas 79.1% with high-risk disease received surgery, radiation, chemotherapy ± autologous stem cell transplant (ASCT). All-cause mortality was elevated across risk groups (SMRhigh = 27.7 [21.4-35.8]; SMRintermediate = 3.3 [1.7-6.5]; SMRlow = 2.8 [1.7-4.8]). SMN risk was increased among high- and intermediate-risk survivors (SIRhigh = 28.0 [18.5-42.3]; SIRintermediate = 3.7 [1.2-11.3]) but did not differ from the US population for survivors of low-risk disease. Compared with siblings, survivors had an increased risk of grade 3-5 CHCs, particularly among those with high-risk disease (HRhigh = 16.1 [11.2-23.2]; HRintermediate = 6.3 [3.8-10.5]; HRlow = 1.8 [1.1-3.1]). Conclusion Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multimorbidity, whereas survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Childhood Cancer Survivors, Late Effects, and a New Model for Understanding Survivorship.
- Author
-
Oeffinger, Kevin C. and Robison, Leslie L.
- Subjects
- *
CANCER treatment complications , *CHILDHOOD cancer , *CANCER patients , *PEDIATRIC drug therapy , *RADIOTHERAPY complications , *DRUG side effects , *CANCER treatment - Abstract
This article presents an editorial on the effects of cancer treatment on young patients who survive. In 2007, approximately 80 percent of children with cancer are cured. The real cost of the cure is damage to the child's developing organ systems from chemotherapy and radiation. The authors say that many survivors are considered cured and are lost to regular checkups for late effect diseases. Promotion of the concept of risk-based health care for childhood cancer survivors should be encouraged.
- Published
- 2007
- Full Text
- View/download PDF
12. Hypogonadism and neurocognitive outcomes among childhood cancer survivors.
- Author
-
Yoshida, Tomoko, Alexander, Tyler, Xing, Mengqi, Mirzaei, Sedigheh, Williams, AnnaLynn M, Lubas, Margaret, Brinkman, Tara M, Chemaitilly, Wassim, Robison, Leslie L, Hudson, Melissa M, Krull, Kevin R, and Delaney, Angela
- Subjects
- *
CHILDHOOD cancer , *NEUROBEHAVIORAL disorders , *HYPOGONADISM - Abstract
Objective Childhood cancer survivors are at risk for hypogonadism. The impact of hypogonadism on neurocognitive impairment and emotional distress in the non-cancer population has been shown; however, the relationship among the childhood cancer survivor population is unknown. We aimed to evaluate the contribution of hypogonadism to neurocognitive impairment and emotional distress among survivors. Design Cross-sectional study using retrospective cohort. Methods In total, 3628 survivors who completed standard neurocognitive tests (six domains: processing speed, memory, executive function, attention, academics, and global cognition) and self-reported emotional distress were included in our study. Participants were stratified by sex and gonadal status. Outcomes were compared between hypogonadal and eugonadal groups by multivariable analysis, adjusting for established predictors, and mediation analyses to determine the direct/indirect effects of hypogonadism on outcomes. Results The hypogonadal group exhibited a higher prevalence of neurocognitive impairment across domains, but no difference in emotional distress. Hypogonadal females exhibited higher relative risk (1.7, 95% CI, 1.2–2.5) for impaired visual processing speed, compared to eugonadal females after adjusting for cancer-related variables. In mediation models, hypogonadism had a significant direct (P <.01) and indirect (from P <.01) impact on impairment in visual processing speed among females. Males demonstrated direct (P =.03) and indirect (P =.04) impact of hypogonadism on motor processing speed. Conclusion Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report.
- Author
-
Goldberg, Jason F, Hyun, Geehong, Ness, Kirsten K, Dixon, Stephanie B, Towbin, Jeffrey A, Rhea, Isaac B, Ehrhardt, Matthew J, Srivastava, Deo Kumar, Mulrooney, Daniel A, Hudson, Melissa M, Robison, Leslie L, Jefferies, John L, Rohatgi, Anand, and Armstrong, Gregory T
- Subjects
- *
DYSLIPIDEMIA , *CHILDHOOD cancer , *CARDIOVASCULAR diseases , *HDL cholesterol , *CANCER survivors , *JUVENILE diseases - Abstract
Background Childhood cancer survivors have increased risk of dyslipidemia and atherosclerotic cardiovascular disease (CVD). The aim of this study was to evaluate the prevalence and associated cardiovascular risks of specific lipid abnormalities among childhood cancer survivors. Methods Comprehensive lipid panel measurements were obtained from 4115 5-year survivors, with 3406 (mean age at evaluation = 35.2 years, SD = 10.4 years) not having previous dyslipidemia diagnosis, as well as 624 age, sex, and race and ethnicity matched community controls. Results Previously undiagnosed dyslipidemia with abnormal low-density lipoprotein (LDL) cholesterol (>160 mg/dL), non–high density lipoprotein (HDL) cholesterol (>190 mg/dL), HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women), and triglycerides (>150 mg/dL) were identified in 4%, 6%, 30%, and 17%, respectively. Survivors without previous dyslipidemia diagnosis had higher LDL cholesterol and non-HDL cholesterol and lower HDL cholesterol than community controls. Cranial radiotherapy (relative risk [RR] = 2.2, 95% confidence interval [CI] = 1.6 to 3.0 for non-HDL cholesterol) and total body irradiation for hematopoietic cell transplantation (RR = 6.7, 95% CI = 3.5 to 13.0 for non-HDL cholesterol; RR = 9.9, 95% CI = 6.0 to 16.3 for triglycerides) were associated with greater risk of dyslipidemia. Diagnoses of low HDL cholesterol (hazard ratio [HR] = 2.9, 95% CI = 1.8 to 4.7) and elevated triglycerides (HR = 3.1, 95% CI = 1.9 to 5.1) were associated with increased risk for myocardial infarction, and diagnoses of high LDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), high non-HDL cholesterol (HR = 2.2, 95% CI = 1.3 to 3.7), low HDL cholesterol (HR = 3.9, 95% CI = 2.8 to 5.4), and elevated triglycerides (HR = 3.8, 95% CI = 2.7 to 5.5) were associated with increased risk for cardiomyopathy. Conclusions Previously undiagnosed dyslipidemia among childhood cancer survivors was associated with increased risk for myocardial infarction and cardiomyopathy. Comprehensive dyslipidemia evaluation and treatment are needed to reduce cardiovascular morbidity in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Evolving therapies, neurocognitive outcomes, and functional independence in adult survivors of childhood glioma.
- Author
-
Papini, Chiara, S., Sedigheh Mirzaei, Xing, Mengqi, Olsson, Ingrid Tonning, Blank, Peter M K de, Lange, Katharine R, Salloum, Ralph, Srivastava, Deokumar, Leisenring, Wendy M, Howell, Rebecca M, Oeffinger, Kevin C, Robison, Leslie L, Armstrong, Gregory T, Krull, Kevin R, and Brinkman, Tara M
- Subjects
- *
GLIOMAS , *CHRONIC diseases , *RADIATION exposure , *PATH analysis (Statistics) , *MARITAL status - Abstract
Background Treatment of childhood glioma has evolved to reduce radiotherapy exposure with the goal of limiting late toxicity. However, the associations between treatment changes and neurocognition, and the contribution of neurocognition and chronic health conditions to attainment of adult independence, remain unknown. Methods Adult survivors of childhood glioma diagnosed in 1970-1999 in the Childhood Cancer Survivor Study (n = 1284; median [minimum-maximum] 30 [18-51] years of age at assessment; 22 [15-34] years from diagnosis) self-reported neurocognitive impairment and chronic health conditions. Multivariable models evaluated associations between changes in treatment exposures (surgery only, chemotherapy [with or without surgery], cranial radiation [with or without chemotherapy and/or surgery]), and neurocognitive impairment. Latent class analysis with 5 indicators (employment, independent living, assistance with routine and/or personal care needs, driver's license, marital or partner status) identified classes of functional independence. Path analysis tested associations among treatment exposures, neurocognitive impairment, chronic health conditions, and functional independence. Statistical tests were 2-sided. Results Cranial radiation exposure decreased over time (51%, 1970s; 46%, 1980s; 27%, 1990s]. However, compared with siblings, survivors with any treatment exposure were at elevated risk for neurocognitive impairment, including surgery only (eg, memory: relative risk = 2.22; task efficiency: relative risk = 1.88; both P < .001). Three classes of functional independence were identified: independent (58%), moderately independent (20%), and nonindependent (22%). Cranial radiation was associated with nonindependence through impaired task efficiency (β = 0.06), sensorimotor (β = 0.06), and endocrine (β = 0.10) chronic health conditions and through the associations between these conditions and task efficiency (each β = 0.04). Sensorimotor and endocrine chronic health conditions were associated with nonindependence through memory. Conclusion Most long-term glioma survivors achieve adult independence. However, functional nonindependence is associated with treatment-related neurocognitive impairment and chronic health conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Neurologic morbidity and functional independence in adult survivors of childhood cancer.
- Author
-
Vuotto, Stefanie C., Wang, Mingjuan, Okcu, M. Fatih, Bowers, Daniel C., Ullrich, Nicole J., Ness, Kirsten K., Li, Chenghong, Srivastava, Deo Kumar, Howell, Rebecca M., Gibson, Todd M., Leisenring, Wendy M., Oeffinger, Kevin C., Robison, Leslie L., Armstrong, Gregory T., Krull, Kevin R., and Brinkman, Tara M.
- Abstract
Objective: To examine associations between neurologic late effects and attainment of independence in adult survivors of childhood cancer treated with central nervous system (CNS)‐directed therapies. Methods: A total of 7881 survivors treated with cranial radiation therapy (n = 4051; CRT) and/or intrathecal methotrexate (n = 4193; IT MTX) ([CNS‐treated]; median age [range] = 25.5 years [18–48]; time since diagnosis = 17.7 years [6.8–30.2]) and 8039 without CNS‐directed therapy reported neurologic conditions including stroke, seizure, neurosensory deficits, focal neurologic dysfunction, and migraines/severe headaches. Functional independence was assessed using latent class analysis with multiple indicators (independent living, assistance with routine and personal care needs, ability to work/attend school, attainment of driver's license, marital/partner status). Multivariable regression models, adjusted for age, sex, race/ethnicity, and chronic health conditions, estimated odds ratios (OR) or relative risks (RR) for associations between neurologic morbidity, functional independence, and emotional distress. Results: Among CNS‐treated survivors, three classes of independence were identified: (1) moderately independent, never married, and non‐independent living (78.7%); (2) moderately independent, unable to drive (15.6%); and (3) non‐independent (5.7%). In contrast to 50% of non‐CNS‐treated survivors and 60% of siblings, a fourth fully independent class of CNS‐treated survivors was not identified. History of stroke (OR = 2.50, 95% CI: 1.70–3.68), seizure (OR = 9.70, 95% CI: 7.37–12.8), neurosensory deficits (OR = 2.67, 95% CI: 2.16–3.31), and focal neurologic dysfunction (OR = 3.05, 95% CI: 2.40–3.88) were associated with non‐independence among CNS‐treated survivors. Non‐independence was associated with emotional distress symptoms. Interpretation: CNS‐treated survivors do not attain full independence comparable to non‐CNS‐treated survivors or siblings. Interventions to promote independence may be beneficial for survivors with treatment‐related neurological sequalae. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.
- Author
-
Armenian, Saro H, Hudson, Melissa M, Lindenfeld, Lanie, Chen, Sitong, Chow, Eric J, Colan, Steven, Collier, Willem, Su, Xiaohong, Marcus, Edward, Echevarria, Meagan, Iukuridze, Aleksi, Robison, Leslie L, Wong, F Lennie, Chen, Ming Hui, and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *CARVEDILOL , *CANCER survivors , *PLACEBOS , *HEART failure patients - Abstract
Carvedilol improves cardiac function in patients with heart failure but remains untested as cardioprotective therapy in long-term childhood cancer survivors (ie, those who have completed treatment for childhood cancer and are in remission) at risk for heart failure due to high-dose anthracycline exposure. We aimed to evaluate the activity and safety of low-dose carvedilol for heart failure risk reduction in childhood cancer survivors at highest risk for heart failure. PREVENT-HF was a randomised, double-blind, phase 2b trial done at 30 hospitals in the USA and Canada. Patients were eligible if they had any cancer diagnosis that resulted in at least 250 mg/m2 cumulative exposure to anthracycline by age 21 years; completed their cancer treatment at least 2 years previously; an ejection fraction of at least 50% or fractional shortening of at least 25%, or both; and bodyweight of at least 40 kg. Patients were randomly assigned (1:1) with automated computer-generated permuted block randomisation (block size of 4), stratified by age at diagnosis, time since diagnosis, and history of chest-directed radiotherapy, to carvedilol (up-titrated from 3·125 g per day to 12·5 mg per day) or placebo orally for 2 years. Participants, staff, and investigators were masked to study group allocation. The primary endpoint was to establish the effect of carvedilol on standardised left ventricular wall thickness–dimension ratio Z score (LVWT/Dz). Treatment effects were analysed with a linear mixed-effects model for normally distributed data with a linear time effect and testing the significance of treatment*time interaction in the modified intention-to-treat (mITT) cohort (ie, all randomly assigned participants who had a baseline and at least one subsequent echocardiogram measurement). Safety was assessed in the ITT population (ie, all randomly assigned participants). This trial was registered with ClinicalTrials.gov , NCT027175073 , and enrolment and follow-up are complete. Between July 3, 2012, and June 22, 2020, 196 participants were enrolled, of whom 182 (93%) were eligible and randomly assigned to either carvedilol (n=89) or placebo (n=93; ITT population). Median age was 24·7 years (IQR 19·6–36·6), 91 (50%) participants were female, 91 (50%) were male, and 119 (65%) were non-Hispanic White. As of data cutoff (June 10, 2022), median follow-up was 725 days (IQR 378–730). 151 (n=75 in the carvedilol group and n=76 in the placebo group) of 182 participants were included in the mITT population, among whom LVWT/Dz was similar between the two groups (−0·14 [95% CI −0·43 to 0·16] in the carvedilol group vs −0·45 [−0·77 to −0·13] in the placebo group; difference 0·31 [95% CI –0·10 to 0·73]; p=0·14). Two (2%) of 89 patients in the carvedilol group two adverse events of grade 2 or higher (n=1 shortness of breath and n=1 arthralgia) and none in the placebo group. There were no adverse events of grade 3 or higher and no deaths. Low-dose carvedilol appears to be safe in long-term childhood cancer survivors at risk for heart failure, but did not result in significant improvement of LVWT/Dz compared with placebo. These results do not support the use of carvedilol for secondary heart failure prevention in anthracycline-exposed childhood cancer survivors. National Cancer Institute, Leukemia & Lymphoma Society, St Baldrick's Foundation, Altschul Foundation, Rally Foundation, American Lebanese Syrian Associated Charities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Interventions with Social Integration Components Addressing Psychosocial Outcomes of Young- and Middle-Aged Adult Cancer Individuals: A Systematic Review.
- Author
-
Poudel, Pragya G., Horan, Madeline R., Brinkman, Tara M., Wang, Zhaoming, Robison, Leslie L., Hudson, Melissa M., and Huang, I-Chan
- Subjects
- *
CANCER patient psychology , *ONLINE information services , *CINAHL database , *SYSTEMATIC reviews , *RESEARCH funding , *INTERPERSONAL relations , *MEDLINE , *SOCIAL integration , *ADULTS , *MIDDLE age - Abstract
Simple Summary: Adult cancer patients and survivors often experience social integration and connectedness chal-lenges. This systematic review summarizes the effect of social integration or social connectedness interventions among young- and middle-aged cancer patients and survivors based on 28 empirical studies published between 2000 and 2021. We found that social integration interventions that utilize technology- and/or non-technology-based platforms show improved social outcomes, increased awareness about available cancer-related resources, decreased perceived isolation, increased knowledge and access to cancer survivorship resources, and improved patient-reported outcomes among cancer individuals versus the comparison individuals. We recommend utilizing suitable platforms, whether technological or non-technological, to facilitate connections between cancer patients/survivors with friends, fellow cancer patients, or society members. This will enable pa-tients/survivors to access essential resources and support, thus enhancing their ability to cope with challenging life situations and ultimately improving social well-being and health outcomes. Background: The majority of adult cancer patients/survivors encounter social challenges (e.g., obtaining social support, maintaining social relationships, feelings of social isolation). This systematic review summarizes intervention studies addressing social integration or social connectedness issues among young- and middle-aged cancer patients/survivors. Methods: We searched the PubMed, CINAHL, and Web of Science databases (January 2000–May 2021) to identify intervention studies that addressed social integration, social connectedness, social support, and social isolation for cancer patients/survivors in young- and middle-aged adulthood (18–64.9 years) through a randomized controlled trial (RCT). We categorized the interventions as technology-based, non-technology-based, and mixed-type (technology- and non-technology-based). Results: A total of 28 studies were identified. These interventions demonstrated improved social outcomes (e.g., increased social support, decreased loneliness), increased awareness of available cancer-related resources, and better patient-reported outcomes among patients/survivors versus controls. Specifically, the use of internet-based discussion sessions was associated with improved social cohesion and social support. Receiving social support from peers through networking sites was associated with improved physical activity. Additionally, implementing mixed-type interventions led to better social support from peer survivors, less fear of social interactions, and improved social connectedness. Conclusions: Using existing technology- and/or non-technology-based platforms to facilitate social connectedness among cancer patients/survivors in young- or middle-aged adulthood can help them cope with stressful life circumstances and improve quality-of-life. Further interventions targeting social integration (e.g., social network interventions) are needed to improve the complex social integration challenges experienced by cancer patients and survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Cancer-Related Worry as a Predictor of 5-yr Physical Activity Level in Childhood Cancer Survivors.
- Author
-
WARE, MEGAN E., DELANEY, ANGELA, KRULL, KEVIN R., BRINKMAN, TARA M., ARMSTRONG, GREGORY T., WILSON, CARMEN L., MULROONEY, DANIEL A., WANG, ZHAOMING, LANCTOT, JENNIFER Q., KRULL, MATTHEW R., PARTIN, ROBYN E., SHELTON, KYLA C., SRIVASTAVA, DEO KUMAR, HUDSON, MELISSA M., ROBISON, LESLIE L., and NESS, KIRSTEN K.
- Subjects
- *
CANCER patient psychology , *CANCER pain , *COUNSELING , *TIME , *SELF-evaluation , *MULTIPLE regression analysis , *ACTIGRAPHY , *TUMORS in children , *PHYSICAL activity , *CANCER patients , *PATIENTS' attitudes , *FACTOR analysis , *DESCRIPTIVE statistics , *HEALTH behavior , *RESEARCH funding , *WORRY - Abstract
Purpose: Cancer-related worry (CRW; concerns related to cancer and its late effects) is prevalent among childhood cancer survivors. Elevated CRW has been associated with self-reported suboptimal physical activity. The aim of this investigation was to describe associations between CRW and objectively assessed physical activity in childhood cancer survivors. Methods: CRW was assessed at a baseline evaluation using six survey items. Weekly minutes of moderate and vigorous physical activity were captured by actigraphy 5.25 (3.8-8.0) yr later. Factor analysis was used to identify types of worry; multiple regression determined independent associations between CRW and moderate and vigorous physical activity adjusting for sex, race, diagnosis, age at baseline, anxiety level at baseline, self-reported physical activity at baseline, and pain interference at baseline. Results: Participants (n = 1223) were an average of 30.9 (SD, 6.9) yr at baseline and 36.1 (SD, 7.1) yr at follow-up. Thirty-seven percent were survivors of leukemia, 26% of non-CNS solid tumors, 19% of lymphoma, 11% of CNS tumors, and 6% of other malignancies. Two types of CRW were identified: "body-focused" and "general fear." Body-focused CRW (β = -19.6, P = 0.012), endorsing pain interference (β = -27.7, P = 0.002) at baseline, and having a diagnosis of CNS tumor (β = -41.3, P = 0.0003) or non-CNS solid tumor (β = -19.4, P = 0.02) were negatively associated with physical activity at follow-up. Conclusions: CRW related to bodily function and appearance is associated with decreased physical activity. Clinicians should consider the potential negative impact of CRW on physical activity levels and provide behavioral counseling. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Medical surveillance of long-term survivors of childhood cancer
- Author
-
Robison, Leslie L. and Hudson, Melissa M.
- Published
- 2007
- Full Text
- View/download PDF
20. Adherence to healthy diet and risk of cardiovascular disease in adult survivors of childhood cancer in the St. Jude Lifetime Cohort: a cross-sectional study.
- Author
-
Lan, Tuo, Wang, Mei, Ehrhardt, Matthew J., Jiang, Shu, Lanctot, Jennifer Q., Armstrong, Gregory T., Hudson, Melissa M., Colditz, Graham A., Robison, Leslie L., and Park, Yikyung
- Subjects
- *
DASH diet , *CHILDHOOD cancer , *PLANT-based diet , *CANCER survivors , *CARDIOVASCULAR diseases , *CELIAC disease , *NON-communicable diseases - Abstract
Background: Whether diet has beneficial effects on cardiovascular disease (CVD) in childhood cancer survivors as in the general population is unknown. Therefore, we examined associations between dietary patterns and risk of CVD in adult survivors of childhood cancer. Methods: Childhood cancer survivors, 18–65 years old in the St Jude Lifetime Cohort (1882 men and 1634 women) were included in the analysis. Dietary patterns were defined by the adherence to the Healthy Eating Index (HEI)–2015, Dietary Approaches to Stop Hypertension (DASH), and alternate Mediterranean diet (aMED) based on a food frequency questionnaire at study entry. CVD cases (323 in men and 213 in women) were defined as participants with at least one grade 2 or higher CVD-related diagnosis at baseline. Multivariable logistic regression adjusted for confounders was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of CVD. Results: Greater adherence to HEI-2015 (OR=0.88, 95% CI: 0.75–1.03, per 10 score increment), DASH (OR=0.85, 95% CI: 0.71–1.01, per 10 score increment), and aMED (OR=0.92, 95% CI: 0.84–1.00, each score increment) were, albeit trending towards significance, associated with a lower risk of CVD in women. HEI-2015 was associated with a non-significantly lower risk of CVD in men (ORQ5 vs. Q1=0.80, 95% CI: 0.50–1.28). These dietary patterns were also associated with a lower risk of CVD in survivors with high underlying CVD risk. Conclusions: As recommended to the general population, a diet rich in plant foods and moderate in animal foods needs to be a part of CVD management and prevention in childhood cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Response‐shift effects in childhood cancer survivors: A prospective study.
- Author
-
Huang, I‐Chan, Sim, Jin‐ah, Srivastava, DeoKumar, Krull, Kevin R., Ness, Kirsten K., Robison, Leslie L., Baker, Justin N., Hudson, Melissa M., and Schwartz, Carolyn E.
- Subjects
- *
CHILDHOOD cancer , *CANCER survivors , *LONGITUDINAL method - Abstract
Background: Treatment‐related late effects can worsen over time among cancer survivors. Such worsening health states may trigger changes in internal standards, values, or conceptualization of quality‐of‐life (QOL). This "response‐shift" phenomenon can jeopardize the validity of QOL assessment, and misrepresent QOL comparisons over time. This study tested response‐shift effects in reporting future‐health concerns among childhood cancer survivors who experienced progression in chronic health conditions (CHCs). Methods: 2310 adult survivors of childhood cancer from St. Jude Lifetime Cohort Study completed a survey and clinical assessment at two or more timepoints. Based on 190 individual CHCs graded for adverse‐event severity, global CHC burden was classified as "progression" or "non‐progression". QOL was assessed using the SF‐36TM eight domains and physical‐ and mental‐component summary scores (PCS, MCS). A single global item measured concerns about future health. Random‐effects models comparing survivors with and without progressive global CHC burden (progressors vs. non‐progressors) evaluated response‐shift effects (recalibration, reprioritization, reconceptualization) in reporting future‐health concerns. Results: Compared with non‐progressors, progressors were more likely to de‐emphasize (or downplay) overall physical and mental health in evaluating future‐health concerns (p‐values<0.05), indicating recalibration response‐shift, and more likely to de‐emphasize physical health earlier rather than later in follow‐up (p‐value<0.05), indicating reprioritization response‐shift. There was evidence for a reconceptualization response‐shift with progressor classification associated with worse‐than‐expected future‐health concerns and physical health, and better‐than‐expected pain and role‐emotional functioning (p‐values<0.05). Conclusion: We identified three types of response‐shift phenomena in reporting concerns about future health among childhood cancer survivors. Survivorship care or research should consider response‐shift effects when interpreting changes in QOL over time. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Health behavior profiles in young survivors of childhood cancer: Findings from the St. Jude Lifetime Cohort Study.
- Author
-
Webster, Rachel Tillery, Dhaduk, Rikeenkumar, Gordon, Mallorie L., Partin, Robyn E., Kunin‐Batson, Alicia S., Brinkman, Tara M., Willard, Victoria W., Allen, Jennifer M., Alberts, Nicole M., Lanctot, Jennifer Q., Ehrhardt, Matthew J., Li, Zhenghong, Hudson, Melissa M., Robison, Leslie L., and Ness, Kirsten K.
- Subjects
- *
HEALTH behavior , *CHILDHOOD cancer , *CANCER survivors , *PHYSICAL mobility , *MOTOR ability , *MENTAL health - Abstract
Background: There is limited understanding of associations between a combination of health behaviors (physical activity, sedentary/screen‐time, diet) and cardiometabolic health risk factors, physical performance, and emotional health among young (<18) childhood cancer survivors (CCS). The aims of this research were to address this gap by 1) deriving health behavior adherence profiles among CCS, and 2) examining associations among demographic, diagnosis and/or treatment exposures, cardiometabolic, physical performance, and emotional functioning with health behavior profile membership. Methods: Participants included 397 CCS (≥5 years post‐diagnosis; 10–17 years old) enrolled in the St. Jude Lifetime Cohort Study who completed physical health evaluations and questionnaires assessing health behaviors and psychological functioning. Latent profile analysis was used to derive profiles of health behavior adherence. Logistic regression and t‐tests were used to examine mean‐level differences and associations between profile membership with demographic, diagnosis, treatment exposures, cardiometabolic health, psychological functioning, and physical performance. Results: Two profiles emerged: inactive‐unhealthy‐diet ("IU") and active‐sedentary‐unhealthy‐diet ("ASU") to guidelines. More participants in IU demonstrated higher resting heart rate (mean [M], 76.54; SD = 12.00) and lower motor proficiency scores (M = 34.73; SD = 29.15) compared to ASU (resting heart rate, M = 71.95, SD = 10.74; motor proficiency, M = 50.40, SD = 31.02). Conclusions: CCS exhibited low adherence to multiple health behavior guidelines, with adherence patterns differentially associated with cardiometabolic health (i.e., resting heart rate) and physical performance. However, robust protection against all health variables was not observed. Findings suggest interventions designed to improve health outcomes should target multiple health behaviors simultaneously. Plain Language Summary: Pediatric cancer survivors are at‐risk for detrimental health outcomes associated with cancer and treatment.Engagement in healthy lifestyle behaviors serves to reduce health vulnerabilities among adult survivors but less is known about associations with lifestyle behaviors on young survivors.This study documents patterns of lifestyle behaviors among survivors of pediatric cancer, factors that increase susceptibility to nonadherence, and associations among lifestyle behaviors and health indicators. Young (<18 years of age) survivors of pediatric cancer exhibit poor adherence to diet and physical activity guidelines. Adherence is associated with clinical health outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort.
- Author
-
Dieffenbach, Bryan V, Murphy, Andrew J, Liu, Qi, Ramsey, Duncan C, Geiger, Erik J, Diller, Lisa R, Howell, Rebecca M, Oeffinger, Kevin C, Robison, Leslie L, Yasui, Yutaka, Armstrong, Gregory T, Chow, Eric J, Weil, Brent R, and Weldon, Christopher B
- Subjects
- *
CHILDHOOD cancer , *CANCER survivors , *EWING'S sarcoma , *CHILDREN'S hospitals , *EARLY death , *FEMALE condoms , *CANCER radiotherapy - Abstract
Multimodal cancer therapy places childhood cancer survivors at increased risk for chronic health conditions, subsequent malignancies, and premature mortality as they age. We aimed to estimate the cumulative burden of late (>5 years from cancer diagnosis), major surgical interventions among childhood cancer survivors, compared with their siblings, and to examine associations between specific childhood cancer treatments and the burden of late surgical interventions. We analysed data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study with longitudinal prospective follow-up of 5-year survivors of childhood cancer (diagnosed before age 21 years) treated at 31 institutions in the USA, with a comparison group of nearest-age siblings of survivors selected by simple random sampling. The primary outcome was any self-reported late, major surgical intervention (defined as any anaesthesia-requiring operation) occurring 5 years or more after the primary cancer diagnosis. The cumulative burden was assessed with mean cumulative counts (MCC) of late, major surgical interventions. Piecewise exponential regression models with calculation of adjusted rate ratios (RRs) evaluated associations between treatment exposures and late, major surgical interventions. Between Jan 1, 1970, and Dec 31, 1999, 25 656 survivors were diagnosed (13 721 male, 11 935 female; median follow-up 21·8 years [IQR 16·5–28·4]; median age at diagnosis 6·1 years [3·0–12·4]); 5045 nearest-age siblings were also included as a comparison group. Survivors underwent 28 202 late, major surgical interventions and siblings underwent 4110 late, major surgical interventions. The 35-year MCC of a late, major surgical intervention was 206·7 per 100 survivors (95% CI 202·7–210·8) and 128·9 per 100 siblings (123·0–134·7). The likelihood of a late, major surgical intervention was higher in survivors versus siblings (adjusted RR 1·8, 95% CI 1·7–1·9) and in female versus male survivors (1·4; 1·4–1·5). Survivors diagnosed in the 1990s (adjusted RR 1·4, 95% CI 1·3–1·5) had an increased likelihood of late surgery compared with those diagnosed in the 1970s. Survivors received late interventions more frequently than siblings in most anatomical regions or organ systems, including CNS (adjusted RR 16·9, 95% CI 9·4–30·4), endocrine (6·7, 5·2–8·7), cardiovascular (6·6, 5·2–8·3), respiratory (5·3, 3·4–8·2), spine (2·4, 1·8–3·2), breast (2·1, 1·7–2·6), renal or urinary (2·0, 1·5–2·6), musculoskeletal (1·5, 1·4–1·7), gastrointestinal (1·4, 1·3–1·6), and head and neck (1·2, 1·1–1·4) interventions. Survivors of Hodgkin lymphoma (35-year MCC 333·3 [95% CI 320·1–346·6] per 100 survivors), Ewing sarcoma (322·9 [294·5–351·3] per 100 survivors), and osteosarcoma (269·6 [250·1–289·2] per 100 survivors) had the highest cumulative burdens of late, major surgical interventions. Locoregional surgery or radiotherapy cancer treatment were associated with undergoing late surgical intervention in the same body region or organ system. Childhood cancer survivors have a significant burden of late, major surgical interventions, a late effect that has previously been poorly quantified. Survivors would benefit from regular health-care evaluations aiming to anticipate impending surgical issues and to intervene early in the disease course when feasible. US National Institutes of Health, US National Cancer Institute, American Lebanese Syrian Associated Charities, and St Jude Children's Research Hospital. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study.
- Author
-
Zhang, Fang Fang, Hudson, Melissa M., Chen, Fan, Li, Zhongyu, Huang, I‐Chan, Bhakta, Nickhill, Ness, Kirsten K., Brinkman, Tara M., Klosky, James, Ojha, Rohit P., Lanctot, Jennifer Q., Robison, Leslie L., and Krull, Kevin R.
- Subjects
- *
DIETARY supplements , *CHILDHOOD cancer , *CANCER survivors , *NUTRITIONAL status , *PHYSICAL mobility - Abstract
Background: Adult survivors of childhood cancer have poor adherence to nutrition guidelines and inadequate intake of dietary vitamins D and E, potassium, fiber, magnesium, and calcium. The contribution of vitamin and mineral supplement use to total nutrient intake in this population is unclear. Methods: We examined the prevalence and dose of nutrient intake among 2570 adult survivors of childhood cancer participating in the St. Jude Lifetime Cohort Study, and the association of dietary supplement use with treatment exposures, symptom burden, and quality of life. Results: Nearly 40% of the adult survivors of cancer survivors reported regular use of dietary supplements. Although cancer survivors who used dietary supplements were less likely to have inadequate intake of several nutrients, they were also more likely to have excessive intake (total nutrient intake ≥ tolerable upper intake levels) of folate (15.4% vs. 1.3%), vitamin A (12.2% vs. 0.2%), iron (27.8% vs. 1.2%), zinc (18.6% vs. 1%), and calcium (5.1% vs. 0.9%) compared with survivors who did not use dietary supplements (all p < 0.05). Treatment exposures, symptom burden, and physical functioning were not associated with supplement use, whereas emotional well‐being and vitality were positively associated with supplement use among childhood cancer survivors. Conclusions: Supplement use is associated with both inadequate and excessive intake of specific nutrients, but positively impacts aspects of quality of life among childhood cancer survivors. Adult survivors of childhood cancer who used dietary supplements were less likely to have inadequate intake of several nutrients but were also more likely to have excessive intake of specific nutrients compared with those who did not use dietary supplements. Health care providers need to monitor dietary supplement use among long‐term survivors of childhood cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Second primary cancers after childhood cancer.
- Author
-
Robison, Leslie L.
- Subjects
- *
TUMORS in children - Abstract
Comments on studies made on the recurrence of second primary cancers after cancer in childhood. Indication of a low absolute risk for recurrence; Prioritization of prevention and monitoring of cancer; Levels of mortality and morbidity in recurrence.
- Published
- 1996
- Full Text
- View/download PDF
26. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.
- Author
-
Dixon, Stephanie B, Liu, Qi, Chow, Eric J, Oeffinger, Kevin C, Nathan, Paul C, Howell, Rebecca M, Leisenring, Wendy M, Ehrhardt, Matthew J, Ness, Kirsten K, Krull, Kevin R, Mertens, Ann C, Hudson, Melissa M, Robison, Leslie L, Yasui, Yutaka, and Armstrong, Gregory T
- Subjects
- *
CHILDHOOD cancer , *CANCER fatigue , *CEREBROVASCULAR disease , *CANCER survivors , *CARDIOVASCULAR diseases risk factors , *COHORT analysis , *MORTALITY - Abstract
5-year survival after childhood cancer does not fully describe life-years lost due to childhood cancer because there are a large number of deaths occurring beyond 5-years (late mortality) related to cancer and cancer treatment. Specific causes of health-related (non-recurrence, non-external) late mortality and risk reduction through modifiable lifestyle and cardiovascular risk factors are not well described. Through using a well-characterised cohort of 5-year survivors of the most common childhood cancers, we evaluated specific health-related causes of late mortality and excess deaths compared with the general US population and identified targets to reduce future risk. In this multi-institutional, hospital-based, retrospective cohort study, late mortality (death ≥5 years from diagnosis) and specific causes of death were evaluated in 34 230 5-year survivors of childhood cancer diagnosed at an age younger than 21 years from 1970 to 1999 at 31 institutions in the USA and Canada; median follow-up from diagnosis was 29 years (range 5–48) in the Childhood Cancer Survivor Study. Demographic, self-reported modifiable lifestyle (ie, smoking, alcohol, physical activity, and BMI) and cardiovascular risk factors (ie, hypertension, diabetes, and dyslipidaemia) associated with health-related mortality (which excludes death from primary cancer and external causes and includes death from late effects of cancer therapy) were evaluated. 40-year cumulative all-cause mortality was 23·3% (95% CI 22·7–24·0), with 3061 (51·2%) of 5916 deaths from health-related causes. Survivors 40 years or more from diagnosis experienced 131 excess health-related deaths per 10 000 person-years (95% CI 111–163), including those due to the top three causes of health-related death in the general population: cancer (absolute excess risk per 10 000 person-years 54, 95% CI 41–68), heart disease (27, 18–38), and cerebrovascular disease (10, 5–17). Healthy lifestyle and absence of hypertension and diabetes were each associated with a 20–30% reduction in health-related mortality independent of other factors (all p values ≤0·002). Survivors of childhood cancer are at excess risk of late mortality even 40 years from diagnosis, due to many of the leading causes of death in the US population. Modifiable lifestyle and cardiovascular risk factors associated with reduced risk for late mortality should be part of future interventions. US National Cancer Institute and the American Lebanese Syrian Associated Charities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Emotional, behavioral, and physical health consequences of loneliness in young adult survivors of childhood cancer: Results from the Childhood Cancer Survivor Study.
- Author
-
Papini, Chiara, Fayad, Ameera A., Wang, Mingjuan, Schulte, Fiona S. M., Huang, I‐Chan, Chang, Yu‐Ping, Howell, Rebecca M., Srivastava, Deokumar, Leisenring, Wendy M., Armstrong, Gregory T., Gibson, Todd M., Robison, Leslie L., Oeffinger, Kevin C., Krull, Kevin R., and Brinkman, Tara M.
- Subjects
- *
LONELINESS , *YOUNG adults , *CHILDHOOD cancer , *CANCER survivors , *HEALTH behavior , *PSYCHOLOGICAL distress - Abstract
Background: Young adults in the general population are at risk of experiencing loneliness, which has been associated with physical and mental health morbidities. The prevalence and consequences of loneliness in young adult survivors of childhood cancer remain unknown. Methods: A total of 9664 young adult survivors of childhood cancer (median age at diagnosis 10.5 years [interquartile range (IQR), 5–15], 27.1 years at baseline [IQR, 23–32]) and 2221 siblings enrolled in the Childhood Cancer Survivor Study completed a self‐reported survey question assessing loneliness on the Brief Symptom Inventory‐18 at baseline and follow‐up (median follow‐up, 6.6 years). Multivariable models evaluated the prevalence of loneliness at baseline only, follow‐up only, and baseline + follow‐up, and its associations with emotional distress, health behaviors, and chronic conditions at follow‐up. Results: Survivors were more likely than siblings to report loneliness at baseline + follow‐up (prevalence ratio [PR] 2.2; 95% confidence interval [CI], 1.7–3.0) and at follow‐up only (PR, 1.4; 95% CI, 1.1–1.7). Loneliness at baseline + follow‐up was associated with elevated risk of anxiety (relative risk [RR], 9.8; 95% CI, 7.5–12.7), depression (RR, 17.9; 95% CI, 14.1–22.7), and current smoking (odds ratio [OR], 1.7; 95% CI, 1.3–2.3) at follow‐up. Loneliness at follow‐up only was associated with suicidal ideation (RR, 1.5; 95% CI, 1.1–2.1), heavy/risky alcohol consumption (RR, 1.3; 95% CI, 1.1–1.5), and new‐onset grade 2–4 chronic conditions (RR, 1.3; 95% CI, 1.0–1.7). Conclusions: Young adult survivors of childhood cancer have elevated risk of experiencing loneliness, which is associated with future emotional distress, risky health behaviors, and new‐onset chronic conditions. Young adult survivors of childhood cancer are at elevated risk of loneliness compared to siblings. Loneliness is associated with future emotional distress, risky health behaviors, new‐onset chronic health conditions, and future poor quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. What Are Risk Factors for and Outcomes of Late Amputation After Treatment for Lower Extremity Sarcoma: A Childhood Cancer Survivor Study Report.
- Author
-
Geiger, Erik J., Liu, Wei, Srivastava, Deo Kumar, Bernthal, Nicholas M., Weil, Brent R., Yasui, Yutaka, Ness, Kirsten K., Krull, Kevin R., Goldsby, Robert E., Oeffinger, Kevin C., Robison, Leslie L., Dieffenbach, Bryan V., Weldon, Christopher B., Gebhardt, Mark C., Howell, Rebecca, Murphy, Andrew J., Leisenring, Wendy M., Armstrong, Gregory T., Chow, Eric J., and Wustrack, Rosanna L.
- Subjects
- *
AMPUTATION , *CHILDHOOD cancer , *TRAUMATIC amputation , *CANCER survivors , *LIMB salvage , *ARTIFICIAL joints - Abstract
Background: Although pediatric lower extremity sarcoma once was routinely treated with amputation, multiagent chemotherapy as well as the evolution of tumor resection and reconstruction techniques have enabled the wide adoption of limb salvage surgery (LSS). Even though infection and tumor recurrence are established risk factors for early amputation (< 5 years) after LSS, the frequency of and factors associated with late amputation (≥ 5 years from diagnosis) in children with sarcomas are not known. Additionally, the resulting psychosocial and physical outcomes of these patients compared with those treated with primary amputation or LSS that was not complicated by subsequent amputation are not well studied. Studying these outcomes is critical to enhancing the quality of life of patients with sarcomas. Questions/purposes: (1) How have treatments changed over time in patients with lower extremity sarcoma who are included in the Childhood Cancer Survivor Study (CCSS), and did primary treatment with amputation or LSS affect overall survival at 25 years among patients who had survived at least 5 years from diagnosis? (2) What is the cumulative incidence of amputation after LSS for patients diagnosed with pediatric lower extremity sarcomas 25 years after diagnosis? (3) What are the factors associated with time to late amputation (≥ 5 years after diagnosis) in patients initially treated with LSS for lower extremity sarcomas in the CCSS? (4) What are the comparative social, physical, and emotional health-related quality of life (HRQOL) outcomes among patients with sarcoma treated with primary amputation, LSS without amputation, or LSS complicated by late amputation, as assessed by CCSS follow-up questionnaires, the SF-36, and the Brief Symptom Inventory-18 at 20 years after cancer diagnosis? Methods: The CCSS is a long-term follow-up study that began in 1994 and is coordinated through St. Jude Children's Research Hospital. It is a retrospective study with longitudinal follow-up of more than 38,000 participants treated for childhood cancer when younger than 21 years at one of 31 collaborating institutions between 1970 and 1999 in the United States and Canada. Participants were eligible for enrollment in the CCSS after they had survived 5 years from diagnosis. Within the CCSS cohort, we included participants who had a diagnosis of lower extremity sarcoma treated with primary amputation (547 patients with a mean age at diagnosis of 13 ± 4 years) or primary LSS (510 patients with a mean age 14 ± 4 years). The LSS cohort was subdivided into LSS without amputation, defined as primary LSS without amputation at the time of latest follow-up; LSS with early amputation, defined as LSS complicated by amputation occurring less than 5 years from diagnosis; or LSS with late amputation, defined as primary LSS in study patients who subsequently underwent amputation 5 years or more from cancer diagnosis. The cumulative incidence of late amputation after primary LSS was estimated. Cox proportional hazards regression with time-varying covariates identified factors associated with late amputation. Modified Poisson regression models were used to compare psychosocial, physical, and HRQOL outcomes among patients treated with primary amputation, LSS without amputation, or LSS complicated by late amputation using validated surveys. Results: More study participants were treated with LSS than with primary amputation in more recent decades. The overall survival at 25 years in this population who survived 5 years from diagnosis was not different between those treated with primary amputation (87% [95% confidence interval [CI] 82% to 91%]) compared with LSS (88% [95% CI 85% to 91%]; p = 0.31). The cumulative incidence of amputation at 25 years after cancer diagnosis and primary LSS was 18% (95% CI 14% to 21%). With the numbers available, the cumulative incidence of late amputation was not different among study patients treated in the 1970s (27% [95% CI 15% to 38%]) versus the 1980s and 1990s (19% [95% CI 13% to 25%] and 15% [95% CI 10% to 19%], respectively; p = 0.15). After controlling for gender, medical and surgical treatment variables, cancer recurrence, and chronic health conditions, gender (hazard ratio [HR] 2.02 [95% CI 1.07 to 3.82]; p = 0.03) and history of prosthetic joint reconstruction (HR 2.58 [95% CI 1.37 to 4.84]; p = 0.003) were associated with an increased likelihood of late amputation. Study patients treated with a primary amputation (relative risk [RR] 2.04 [95% CI 1.15 to 3.64]) and LSS complicated by late amputation (relative risk [RR] 3.85 [95% CI 1.66 to 8.92]) were more likely to be unemployed or unable to attend school than patients treated with LSS without amputation to date. The CCSS cohort treated with primary amputation and those with LSS complicated by late amputation reported worse physical health scores than those without amputation to date, although mental and emotional health outcomes did not differ between the groups. Conclusion: There is a substantial risk of late amputation after LSS, and both primary and late amputation status are associated with decreased physical HRQOL outcomes. Children treated for sarcoma who survive into adulthood after primary amputation and those who undergo late amputation after LSS may benefit from interventions focused on improving physical function and reaching educational and employment milestones. Efforts to improve the physical function of people who have undergone amputation either through prosthetic design or integration into the residuum should be supported. Understanding factors associated with late amputation in the setting of more modern surgical approaches and implants will help surgeons more effectively manage patient expectations and adjust practice to mitigate these risks over the life of the patient. Level of Evidence: Level III, therapeutic study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Distinct DNA methylation signatures associated with blood lipids as exposures or outcomes among survivors of childhood cancer: a report from the St. Jude lifetime cohort.
- Author
-
Dong, Qian, Chen, Cheng, Song, Nan, Qin, Na, Plonski, Noel-Marie, Finch, Emily R., Shelton, Kyla, Easton, John, Mulder, Heather, Plyer, Emily, Neale, Geoffrey, Walker, Emily, Li, Qian, Huang, I-Chan, Zhang, Jinghui, Wang, Hui, Hudson, Melissa M., Robison, Leslie L., Ness, Kirsten K., and Wang, Zhaoming
- Subjects
- *
BLOOD lipids , *CHILDHOOD cancer , *DNA methylation , *CANCER survivors , *LIPID metabolism , *MICROSATELLITE repeats , *BLOOD lipoproteins - Abstract
Background: DNA methylation (DNAm) plays an important role in lipid metabolism, however, no epigenome-wide association study (EWAS) of lipid levels has been conducted among childhood cancer survivors. Here, we performed EWAS analysis with longitudinally collected blood lipid data from survivors in the St. Jude lifetime cohort study. Methods: Among 2052 childhood cancer survivors of European ancestry (EA) and 370 survivors of African ancestry (AA), four types of blood lipids, including high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), and triglycerides (TG), were measured during follow-up beyond 5-years from childhood cancer diagnosis. For the exposure EWAS (i.e., lipids measured before blood draw for DNAm), the DNAm level was an outcome variable and each of the blood lipid level was an exposure variable; vice versa for the outcome EWAS (i.e., lipids measured after blood draw for DNAm). Results: Among EA survivors, we identified 43 lipid-associated CpGs in the HDL (n = 7), TC (n = 3), and TG (n = 33) exposure EWAS, and 106 lipid-associated CpGs in the HDL (n = 5), LDL (n = 3), TC (n = 4), and TG (n = 94) outcome EWAS. Among AA survivors, we identified 15 lipid-associated CpGs in TG exposure (n = 6), HDL (n = 1), LDL (n = 1), TG (n = 5) and TC (n = 2) outcome EWAS with epigenome-wide significance (P < 9 × 10−8). There were no overlapping lipids-associated CpGs between exposure and outcome EWAS among EA and AA survivors, suggesting that the DNAm changes of different CpGs could be the cause or consequence of blood lipid levels. In the meta-EWAS, 12 additional CpGs reached epigenome-wide significance. Notably, 32 out of 74 lipid-associated CpGs showed substantial heterogeneity (Phet < 0.1 or I2 > 70%) between EA and AA survivors, highlighting differences in DNAm markers of blood lipids between populations with diverse genetic ancestry. Ten lipid-associated CpGs were cis-expression quantitative trait methylation with their DNAm levels associated with the expression of corresponding genes, out of which seven were negatively associated. Conclusions: We identified distinct signatures of DNAm for blood lipids as exposures or outcomes and between EA and AA survivors, revealing additional genes involved in lipid metabolism and potential novel targets for controlling blood lipids in childhood cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Ten Considerations for Integrating Patient-Reported Outcomes into Clinical Care for Childhood Cancer Survivors.
- Author
-
Horan, Madeline R., Sim, Jin-ah, Krull, Kevin R., Ness, Kirsten K., Yasui, Yutaka, Robison, Leslie L., Hudson, Melissa M., Baker, Justin N., and Huang, I-Chan
- Subjects
- *
MEDICAL quality control , *HEALTH services accessibility , *HEALTH outcome assessment , *HEALTH status indicators , *MEDICAL technology , *TUMORS in children , *CANCER patients , *QUALITY of life , *QUALITY assurance , *RESEARCH funding , *CANCER patient medical care - Abstract
Simple Summary: Patient-reported outcome measures (PROMs) are a useful way to assess the subjective experiences of health-related quality of life, functional status, symptoms, and other outcomes in childhood cancer survivors. In survivorship care, PROMs can be used to monitor health status and inform medical decision making. This article provides 10 important considerations for clinicians when they are assessing patient-reported outcomes for childhood cancer survivors. From choosing the right measure to selecting a strategy for clinical response, the purpose of these considerations is to support clinicians in implementing PROMs in their practice while keeping in mind some of the practical barriers and solutions of using PROMs with childhood cancer survivors. We end with an example of a framework for integrating PROMs into the clinical workflow that uses cutting-edge technologies (e.g., mHealth, natural language processing, and machine learning) to minimize interruptions to the clinical workflow and maximize the powerful utility of PROMs in cancer survivorship care. Patient-reported outcome measures (PROMs) are subjective assessments of health status or health-related quality of life. In childhood cancer survivors, PROMs can be used to evaluate the adverse effects of cancer treatment and guide cancer survivorship care. However, there are barriers to integrating PROMs into clinical practice, such as constraints in clinical validity, meaningful interpretation, and technology-enabled administration of the measures. This article discusses these barriers and proposes 10 important considerations for appropriate PROM integration into clinical care for choosing the right measure (considering the purpose of using a PROM, health profile vs. health preference approaches, measurement properties), ensuring survivors complete the PROMs (data collection method, data collection frequency, survivor capacity, self- vs. proxy reports), interpreting the results (scoring methods, clinical meaning and interpretability), and selecting a strategy for clinical response (integration into the clinical workflow). An example framework for integrating novel patient-reported outcome (PRO) data collection into the clinical workflow for childhood cancer survivorship care is also discussed. As we continuously improve the clinical validity of PROMs and address implementation barriers, routine PRO assessment and monitoring in pediatric cancer survivorship offer opportunities to facilitate clinical decision making and improve the quality of survivorship care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Premature Aging as an Accumulation of Deficits in Young Adult Survivors of Pediatric Cancer.
- Author
-
Williams, AnnaLynn M, Mandelblatt, Jeanne, Wang, Mingjuan, Armstrong, Gregory T, Bhakta, Nickhill, Brinkman, Tara M, Chemaitilly, Wassim, Ehrhardt, Matthew J, Mulrooney, Daniel A, Small, Brent J, Wang, Zhaoming, Srivastava, Deokumar, Robison, Leslie L, Hudson, Melissa M, Ness, Kirsten K, and Krull, Kevin R
- Subjects
- *
PREMATURE aging (Medicine) , *CHILDHOOD cancer , *YOUNG adults , *CANCER survivors , *RACE , *CANCER fatigue - Abstract
Background: We aimed to characterize premature aging as an accumulation of deficits in survivors of pediatric cancer compared to community controls and examine associations with host/treatment factors, neurocognition, and mortality.Methods: Pediatric cancer survivors (N = 4,000, median age 28.6 [IQR 23-35], 20 [15-27] years post-diagnosis) and community controls (N = 638, median age 32 [25-40]) completed clinical assessments, questionnaires, and were followed for mortality through April 30th, 2020 (mean [SD] follow-up 7.0 [3.4] years). A deficit accumulation index (DAI) score was calculated from 44 aging-related items including: self-reported daily function, psychosocial symptoms, and health conditions. Items were weighted from 0 (absent) to 1 (present/most severe), summed and divided by the total yielding a ratio (higher=more deficits). Scores <0.20 are robust and 0.06 is a clinically meaningful difference. Linear regression compared the DAI in survivors and controls with an age*survivor/control interaction. Logistic regression and Cox-proportional hazards estimated the risk of neurocognitive impairment and death. Models were minimally adjusted for age, sex, and race andethnicity.Results: The adjusted mean DAI among survivors at age 30 years was 0.16 corresponding to age 63 in controls (33 years premature aging; β = 0.07 95%CI 0.06-0.08; p<.001). Cranial/abdominal radiation, alkylators, platinum, and neurosurgery were associated with worse DAI (p's≤.001). Higher scores were associated with increased risk of neurocognitive impairment in all domains (p's<.001) and increased risk of death (DAI 0.20-0.35 HR = 2.80, 95%CI 1.97-3.98; DAI ≥0.35 HR = 5.08, 95%CI 3.52-7.34).Conclusion: Pediatric cancer survivors experience significant premature aging. The DAI may be used to identify survivors at greatest risk of poor health outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
32. Inflated expectations: Rare-variant association analysis using public controls.
- Author
-
Kim, Jung, Karyadi, Danielle M., Hartley, Stephen W., Zhu, Bin, Wang, Mingyi, Wu, Dongjing, Song, Lei, Armstrong, Gregory T., Bhatia, Smita, Robison, Leslie L., Yasui, Yutaka, Carter, Brian, Sampson, Joshua N., Freedman, Neal D., Goldstein, Alisa M., Mirabello, Lisa, Chanock, Stephen J., Morton, Lindsay M., Savage, Sharon A., and Stewart, Douglas R.
- Subjects
- *
FALSE discovery rate , *STATISTICAL significance - Abstract
The use of publicly available sequencing datasets as controls (hereafter, "public controls") in studies of rare variant disease associations has great promise but can increase the risk of false-positive discovery. The specific factors that could contribute to inflated distribution of test statistics have not been systematically examined. Here, we leveraged both public controls, gnomAD v2.1 and several datasets sequenced in our laboratory to systematically investigate factors that could contribute to the false-positive discovery, as measured by λΔ95, a measure to quantify the degree of inflation in statistical significance. Analyses of datasets in this investigation found that 1) the significantly inflated distribution of test statistics decreased substantially when the same variant caller and filtering pipelines were employed, 2) differences in library prep kits and sequencers did not affect the false-positive discovery rate and, 3) joint vs. separate variant-calling of cases and controls did not contribute to the inflation of test statistics. Currently available methods do not adequately adjust for the high false-positive discovery. These results, especially if replicated, emphasize the risks of using public controls for rare-variant association tests in which individual-level data and the computational pipeline are not readily accessible, which prevents the use of the same variant-calling and filtering pipelines on both cases and controls. A plausible solution exists with the emergence of cloud-based computing, which can make it possible to bring containerized analytical pipelines to the data (rather than the data to the pipeline) and could avert or minimize these issues. It is suggested that future reports account for this issue and provide this as a limitation in reporting new findings based on studies that cannot practically analyze all data on a single pipeline. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Clinical Assessment of Late Health Outcomes in Survivors of Wilms Tumor.
- Author
-
Foster, Kayla L., Mirzaei Salehabadi, Sedigheh, Green, Daniel M., Xing, Mengqi, Ness, Kirsten K., Krull, Kevin R., Brinkman, Tara M., Ehrhardt, Matthew J., Chemaitilly, Wassim, Dixon, Stephanie B., Bhakta, Nickhill, Brennan, Rachel C., Krasin, Matthew J., Davidoff, Andrew M., Robison, Leslie L., Hudson, Melissa M., and Mulrooney, Daniel A.
- Subjects
- *
DACTINOMYCIN , *NEPHRECTOMY , *CONFIDENCE intervals , *FUNCTIONAL status , *CHILDREN'S hospitals , *MULTIPLE regression analysis , *DOXORUBICIN , *HEALTH outcome assessment , *HEALTH status indicators , *RETROSPECTIVE studies , *CANCER patients , *NEPHROBLASTOMA , *TUMORS in children , *RESEARCH funding , *COGNITIVE testing , *RADIOTHERAPY , *LONGITUDINAL method , *POISSON distribution , *VINCRISTINE , *TUMOR grading - Abstract
OBJECTIVES: We aimed to clinically characterize the health, neurocognitive, and physical function outcomes of curative treatment of Wilms tumor. METHODS: Survivors ofWilms tumor (n = 280) participating in the St. Jude Lifetime Cohort, a retrospective study with prospective follow-up of individuals treated for childhood cancer at St. Jude Children's Research Hospital, were clinically evaluated and compared to age and sex-matched controls (n = 625). Health conditions were graded per a modified version of the National Cancer Institute's Common Terminology Criteria for Adverse Events. Standardized neurocognitive testing was graded by using age-adjusted z-scores. Impaired physical function was defined by age- and sexmatched z-scores >1.5 SD below controls. Modified Poisson regression was used to compare the prevalence of conditions and multivariable logistic regression to examine treatment associations. RESULTS: Median age at evaluation was similar between survivors and controls (30.5 years [9.0--58.0] and 31.0 [12.0-70.0]). Therapies included nephrectomy (100%), vincristine (99.3%), dactinomycin (97.9%), doxorubicin (66.8%), and abdominal (59.3%) and/or chest radiation (25.0%). By age 40 years, survivors averaged 12.7 (95% confidence interval [CI] 11.7-13.8) grade 1-4 and 7.5 (CI: 6.7-8.2) grade 2 to 4 health conditions, compared to 4.2 (CI: 3.9-4.6) and 2.3 (CI: 2.1-2.5), respectively, among controls. Grade 2 to 4 endocrine (53.9%), cardiovascular (26.4%), pulmonary (18.2%), neurologic (8.6%), neoplastic (7.9%), and kidney (7.2%) conditions were most prevalent. Survivors exhibited neurocognitive and physical performance impairments. CONCLUSIONS: Wilms tumor survivors experience a threefold higher burden of chronic health conditions compared to controls and late neurocognitive and physical function deficits. Individualized clinical management, counseling, and surveillance may improve long-term health maintenance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer.
- Author
-
Song, Nan, Sim, Jin-Ah, Dong, Qian, Zheng, Yinan, Hou, Lifang, Li, Zhenghong, Hsu, Chia-Wei, Pan, Haitao, Mulder, Heather, Easton, John, Walker, Emily, Neale, Geoffrey, Wilson, Carmen L., Ness, Kirsten K., Krull, Kevin R., Srivastava, Deo Kumar, Yasui, Yutaka, Zhang, Jinghui, Hudson, Melissa M., and Robison, Leslie L.
- Published
- 2022
- Full Text
- View/download PDF
35. Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts.
- Author
-
Richard, Melissa A., Mostoufi-Moab, Sogol, Rathore, Nisha, Baedke, Jessica, Brown, Austin L., Chanock, Stephen J., Friedman, Danielle N., Gramatges, M. Monica, Howell, Rebecca M., Kamdar, Kala Y., Leisenring, Wendy M., Meacham, Lillian R., Morton, Lindsay M., Oeffinger, Kevin, Robison, Leslie L., Sapkota, Yadav, Sklar, Charles A., Armstrong, Gregory T., Bhatia, Smita, and Lupo, Philip J.
- Subjects
- *
CHILDHOOD cancer , *CANCER survivors , *DIABETES , *RECEIVER operating characteristic curves , *DISEASE risk factors - Abstract
PURPOSE: To characterize germline genetic risk factors of diabetes mellitus among long-term survivors of childhood cancer. METHODS: Adult survivors of childhood cancer from the Childhood Cancer Survivor Study (CCSS) Original Cohort (n = 5,083; 383 with diabetes) were used to conduct a discovery genome-wide association study. Replication was performed using the CCSS Expansion (n = 2,588; 40 with diabetes) and the St Jude Lifetime (SJLIFE; n = 3,351; 208 with diabetes) cohorts. Risk prediction models, stratified on exposure to abdominal radiation, were calculated using logistic regression including attained age, sex and body mass index, diagnosis, alkylating chemotherapy, age at cancer diagnosis, and a polygenic risk score (PRS) on the basis of 395 diabetes variants from the general population. Area under the receiver operating characteristic curve (AUC) was calculated for models on the basis of traditional risk factors, clinical risk factors, and PRS. RESULTS: There was a genome-wide significant association of rs55849673-A with diabetes among survivors (odds ratio, 2.9; 95% CI, 2.0 to 4.2; P = 3.7 × 10−8), which is related to expression of ERCC6L2 in the Genotype-Tissue Expression project. The association of rs55849673-A was observed largely among survivors not exposed to abdominal radiation (odds ratio = 3.5, P = 1.1 × 10−7) and the frequency of rs55849673-A was consistently higher among diabetic survivors in the CCSS Expansion and SJLIFE cohorts. Risk prediction models including traditional diabetes risk factors, clinical risk factors and PRS had an optimism-corrected AUC of 0.801, with an AUC of 0.751 in survivors treated with abdominal radiation versus 0.813 in survivors who did not receive abdominal radiation. CONCLUSION: There is evidence for a novel locus of diabetes among survivors not exposed to abdominal radiation. Further refinement and validation of clinic-based risk prediction models for diabetes among long-term survivors of childhood cancer is warranted. @melissaarichard et al report germline genetic and treatment-related effects for diabetes mellitus in long-term survivors of childhood cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Late Effects of Treatment for Childhood Hodgkin's Disease.
- Author
-
Bhatia, Smita, Robison, Leslie L., and Meadows, Anna T.
- Subjects
- *
LETTERS to the editor , *HODGKIN'S disease in children , *THERAPEUTICS - Abstract
A reply by Smita Bhatia, Leslie L. Robison and Anna T. Meadows to letters to the editor about their article "Breast cancer and other second neoplasms after childhood Hodgkin's disease," in the March 21, 1996 issue is presented.
- Published
- 1996
- Full Text
- View/download PDF
37. Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease.
- Author
-
Bhatia, Smita, Robison, Leslie L., Oberlin, Odile, Greenberg, Mark, Bunin, Greta, Fossati-Bellani, Franca, and Meadows, Anna T.
- Subjects
- *
HODGKIN'S disease in children , *CANCER research - Abstract
Background: Patients who survive Hodgkin's disease are at increased risk for second neoplasms. As survival times increase, solid tumors are emerging as a serious long-term complication. Methods: The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to determine the incidence of second neoplasms and the risk factors associated with them. Results: In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3). The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent). Breast cancer was the most common solid tumor (standardized incidence ratio, 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age. Older age (10 to 16 vs. <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs. <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer. The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia. Conclusions: The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women. (N Engl J Med 1996;334:745-51.) [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
38. 5 The Impact of Sex and Associations With Treatment Exposures on Neurocognitive Impairment in Pediatric Cancer Survivors: A report from the Childhood Cancer Survivor Study.
- Author
-
Peterson, Rachel K, Chen, Yan, Oeffinger, Kevin, Yasui, Yutaka, Leisenring, Wendy, Armstrong, Gregory T, Robison, Leslie L, Howell, Rebecca M, Mostoufi-Moab, Sogol, Gilleland Marchak, Jordan, Krull, Kevin R., and Edelstein, Kim
- Subjects
- *
SEX factors in disease , *CHILDHOOD cancer , *CANCER survivors , *SEXUAL dimorphism , *HODGKIN'S disease - Abstract
Objective: Sexual dimorphism in human brain structure and behavior is influenced by exposure to sex hormones during critical developmental periods. In children, cancer and cancer treatments may alter hormone activity and brain development, impacting neurocognitive functions. Participants and Methods: Five-year survivors of childhood cancer (N=15,560) diagnosed at <21 years from 1970 to 1999, and 3,206 siblings from the Childhood Cancer Survivor Study completed the Neurocognitive Questionnaire (NCQ), a measure of self-reported task efficiency (TE), emotion regulation (ER), Organization, and working memory (WM). We compared rates of cognitive impairment (i.e., NCQ scores >90th percentile) in survivors and same-sex siblings, and sex differences in risk factors for cognitive impairment (i.e., treatment exposures, chronic health conditions (CHCs), cancer diagnosis, age at diagnosis) using modified Poisson regressions. Results: Survivors were more likely to report cognitive impairment than same-sex siblings (Males: TE OR=2.3, p<.001; ER OR=1.7, p=.008; Organization OR=1.5, p=.04; WM OR=2.3, p<.001. Females: TE OR=2.6, p<.001; ER OR=1.9, p<.001; Organization OR=1.5, p=.02; WM OR=2.6, p<.001). Within survivors, females were more likely than males to report impairment in TE (OR=1.2, p=.001), ER (OR=1.5, p<.001), and WM (OR=1.2, p<.001). There were no sex differences in symptom severity in siblings (all ps>.05). Risk factors for cognitive impairment in survivors included cranial radiation dose (TE <20Gy OR=1.5, p=.008, ≥20Gy OR=2.5, p<.001; ER OR=1.5, p<.001; Organization <20 Gy OR=1.4, p<.001; < WM 20 Gy OR=1.8, p<.001, ≥20Gy OR=2.7, p<.001), presence of moderate to severe CHCs (TE 1 CHC OR=1.9, p<.001, >1 CHC OR=3.6, p<.001; ER 1 CHC OR=1.7, p<.001, >1 CHC OR=2.2, p<.001; Organization 1 CHC OR=1.5, p=.001, >1 CHC OR=2.5, p<.001; WM 1 CHC OR=1.8, p<.001, >1 CHC OR=4.1, p<.001). There were sex differences in cognitive impairment risk factors in survivors. In females, cranial radiation dose (<20 Gy TE OR=1.6, p=.02; ≥20Gy TE OR=1.4, p=.01), leukemia diagnosis (TE OR=1.4, p=.02), or diagnosis age between 3-5 years (WM OR=1.4, p=.02) conferred higher risk for cognitive impairment compared to males with the same history. Females diagnosed with Hodgkin's lymphoma (Organization OR=0.61, p=.05) or non-Hodgkin's lymphoma (Organization OR=0.55, p=.03) were at lower risk for cognitive impairment compared to males. Conclusions: We found sex-specific differences in rates of, and risk factors for, neurocognitive impairment, suggesting a sex vulnerability. Future studies examining interactions between sex hormones and treatment exposures during brain development will enable tailoring treatments follow-up interventions to ensure that quality of life is maximized. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer.
- Author
-
Dong, Qian, Song, Nan, Qin, Na, Chen, Cheng, Li, Zhenghong, Sun, Xiaojun, Easton, John, Mulder, Heather, Plyler, Emily, Neale, Geoffrey, Walker, Emily, Li, Qian, Ma, Xiaotu, Chen, Xiang, Huang, I-Chan, Yasui, Yutaka, Ness, Kirsten K., Zhang, Jinghui, Hudson, Melissa M., and Robison, Leslie L.
- Subjects
- *
GENOME-wide association studies , *CHILDHOOD cancer , *GENETIC variation , *CANCER survivors , *LOCUS (Genetics) , *EPIGENETICS - Abstract
Background: Increased epigenetic age acceleration (EAA) in survivors of childhood cancer is associated with specific treatment exposures, unfavorable health behaviors, and presence of certain chronic health conditions. To better understand inter-individual variability, we investigated the genetic basis underlying EAA. Methods: Genome-wide association studies of EAA based on multiple epigenetic clocks (Hannum, Horvath, PhenoAge, and GrimAge) were performed. MethylationEPIC BeadChip array and whole-genome sequencing data were generated with blood-derived DNA from participants in the St. Jude Lifetime Cohort Study (discovery: 2138 pre-existing and 502 newly generated data, all survivors; exploratory: 282 community controls). Linear regression models were fit for each epigenetic age against the allelic dose of each genetic variant, adjusting for age at sampling, sex, and cancer treatment exposures. Fixed-effects meta-analysis was used to combine summary statistics from two discovery data sets. LD (Linkage disequilibrium) score regression was used to estimate single-nucleotide polymorphism (SNP)-based heritability. Results: For EAA-Horvath, a genome-wide significant association was mapped to the SELP gene with the strongest SNP rs732314 (meta-GWAS: β=0.57, P=3.30×10-11). Moreover, the stratified analysis of the association between rs732314 and EAA-Horvath showed a substantial heterogeneity between children and adults (meta-GWAS: β=0.97 vs. 0.51, I2=73.1%) as well as between survivors with and without chest/abdominal/pelvic-RT exposure (β=0.64 vs. 0.31, I2=66.3%). For EAA-Hannum, an association was mapped to the HLA locus with the strongest SNP rs28366133 (meta-GWAS: β=0.78, P=3.78×10-11). There was no genome-wide significant hit for EAA-PhenoAge or EAA-GrimAge. Interestingly, among community controls, rs732314 was associated with EAA-Horvath (β=1.09, P=5.43×10-5), whereas rs28366133 was not associated with EAA-Hannum (β=0.21, P=0.49). The estimated heritability was 0.33 (SE=0.20) for EAA-Horvath and 0.17 (SE=0.23) for EAA-Hannum, but close to zero for EAA-PhenoAge and EAA-GrimAge. Conclusions: We identified novel genetic variants in the SELP gene and HLA region associated with EAA-Horvath and EAA-Hannum, respectively, among survivors of childhood cancer. The new genetic variants in combination with other replicated known variants can facilitate the identification of survivors at higher risk in developing accelerated aging and potentially inform drug targets for future intervention strategies among vulnerable survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer.
- Author
-
Dong, Qian, Song, Nan, Qin, Na, Chen, Cheng, Li, Zhenghong, Sun, Xiaojun, Easton, John, Mulder, Heather, Plyler, Emily, Neale, Geoffrey, Walker, Emily, Li, Qian, Ma, Xiaotu, Chen, Xiang, Huang, I-Chan, Yasui, Yutaka, Ness, Kirsten K., Zhang, Jinghui, Hudson, Melissa M., and Robison, Leslie L.
- Subjects
- *
GENOME-wide association studies , *CHILDHOOD cancer , *GENETIC variation , *CANCER survivors , *LOCUS (Genetics) , *EPIGENETICS - Abstract
Background: Increased epigenetic age acceleration (EAA) in survivors of childhood cancer is associated with specific treatment exposures, unfavorable health behaviors, and presence of certain chronic health conditions. To better understand inter-individual variability, we investigated the genetic basis underlying EAA. Methods: Genome-wide association studies of EAA based on multiple epigenetic clocks (Hannum, Horvath, PhenoAge, and GrimAge) were performed. MethylationEPIC BeadChip array and whole-genome sequencing data were generated with blood-derived DNA from participants in the St. Jude Lifetime Cohort Study (discovery: 2138 pre-existing and 502 newly generated data, all survivors; exploratory: 282 community controls). Linear regression models were fit for each epigenetic age against the allelic dose of each genetic variant, adjusting for age at sampling, sex, and cancer treatment exposures. Fixed-effects meta-analysis was used to combine summary statistics from two discovery data sets. LD (Linkage disequilibrium) score regression was used to estimate single-nucleotide polymorphism (SNP)-based heritability. Results: For EAA-Horvath, a genome-wide significant association was mapped to the SELP gene with the strongest SNP rs732314 (meta-GWAS: β=0.57, P=3.30×10-11). Moreover, the stratified analysis of the association between rs732314 and EAA-Horvath showed a substantial heterogeneity between children and adults (meta-GWAS: β=0.97 vs. 0.51, I2=73.1%) as well as between survivors with and without chest/abdominal/pelvic-RT exposure (β=0.64 vs. 0.31, I2=66.3%). For EAA-Hannum, an association was mapped to the HLA locus with the strongest SNP rs28366133 (meta-GWAS: β=0.78, P=3.78×10-11). There was no genome-wide significant hit for EAA-PhenoAge or EAA-GrimAge. Interestingly, among community controls, rs732314 was associated with EAA-Horvath (β=1.09, P=5.43×10-5), whereas rs28366133 was not associated with EAA-Hannum (β=0.21, P=0.49). The estimated heritability was 0.33 (SE=0.20) for EAA-Horvath and 0.17 (SE=0.23) for EAA-Hannum, but close to zero for EAA-PhenoAge and EAA-GrimAge. Conclusions: We identified novel genetic variants in the SELP gene and HLA region associated with EAA-Horvath and EAA-Hannum, respectively, among survivors of childhood cancer. The new genetic variants in combination with other replicated known variants can facilitate the identification of survivors at higher risk in developing accelerated aging and potentially inform drug targets for future intervention strategies among vulnerable survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Concordance between self-reported sleep and actigraphy-assessed sleep in adult survivors of childhood cancer: the impact of psychological and neurocognitive late effects.
- Author
-
Lubas, Margaret M., Szklo-Coxe, Mariana, Mandrell, Belinda N., Howell, Carrie R., Ness, Kirsten K., Srivastava, Deo Kumar, Hudson, Melissa M., Robison, Leslie L., Krull, Kevin R., and Brinkman, Tara M.
- Subjects
- *
PSYCHOLOGICAL factors , *CHILDHOOD cancer , *CANCER survivors , *SLEEP , *MEMORY disorders - Abstract
Purpose: To examine self-reported (30-day) sleep versus nightly actigraphy-assessed sleep concordance in long-term survivors of childhood cancer. Methods: Four hundred seventy-seven participants enrolled in the St. Jude Lifetime Cohort (53.5% female, median (range) age 34.3 (19.3–61.6) years, 25.4 (10.9–49.3) years from diagnosis) completed the Pittsburgh Sleep Quality Index and ≥ 3 nights of actigraphy. Participants had neurocognitive impairment and/or a self-reported prolonged sleep onset latency (SOL). Self-reported 30-day sleep and nightly actigraphic sleep measures for sleep duration, SOL, and sleep efficiency (SE) were converted into ordinal categories for calculation of weighted kappa coefficients. General linear models estimated associations between measurement concordance and late effects. Results: Agreements between self-reported and actigraphic measures were slight to fair for sleep duration and SOL measures (kw = 0.20 and kw = 0.22, respectively; p < 0.0001) and poor for SE measures (kw = 0.00, p = 0.79). In multivariable models, severe fatigue and poor sleep quality were significantly associated with greater absolute differences between self-reported and actigraphy-assessed sleep durations (B = 26.6 [p < 0.001] and B = 26.8 [p = 0.01], respectively). Survivors with (versus without) memory impairment had a 44-min higher absolute difference in sleep duration (B = 44.4, p < 0.001). Survivors with, versus without, depression and poor sleep quality had higher absolute discrepancies of SOL (B = 24.5 [p = 0.01] and B = 16.4 [p < 0.0001], respectively). Poor sleep quality was associated with a 12% higher absolute difference in SE (B = 12.32, p < 0.0001). Conclusions: Self-reported sleep and actigraphic sleep demonstrated discordance in our sample. Several prevalent late effects were statistically significantly associated with increased measurement discrepancy. Future studies should consider the impacts of late effects on sleep assessment in adult survivors of childhood cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia.
- Author
-
Lim, Joshua Yew‐Suang, Bhatia, Smita, Robison, Leslie L., and Yang, Jun J.
- Subjects
- *
LYMPHOBLASTIC leukemia , *HISPANIC Americans , *RACE , *ETHNICITY , *LEUKEMIA , *DEMOGRAPHIC characteristics - Abstract
Although the cure rates of childhood acute lymphoblastic leukemia (ALL) have improved dramatically in the past 40 years, not all children have benefited equally from this impressive progress. Racial and ethnic disparities in the incidence and treatment outcome of childhood ALL persist, with Hispanic children having an elevated risk of developing ALL and one of the lowest survival rates after ALL therapy. A critical barrier to progress is the lack of an understanding of the causes of ALL disparities, particularly racial and ethnic differences in ALL biology. In this review, the authors summarize the current knowledge on population variation in childhood ALL incidence and treatment outcome, discuss the contributing genetic and nongenetic variables, and highlight possible therapeutic interventions to mitigate disparities in ALL. Cancer 2014;120:955-962. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor.
- Author
-
Henderson, Tara O., Fowler, Brynn W., Hamann, Haley A., Nathan, Paul C., Whitton, Jillian, Leisenring, Wendy M., Oeffinger, Kevin C., Neglia, Joseph P., Turcotte, Lucie M., Arnold, Michael A., Conces, Miriam R., Howell, Rebecca M., Robison, Leslie L., Armstrong, Gregory T., and Alexander, Kenneth A.
- Subjects
- *
VULVAR cancer , *CHILDHOOD cancer , *CANCER survivors , *PAPILLOMAVIRUS diseases , *PAPILLOMAVIRUSES , *CERVIX uteri - Abstract
Background: Human papillomavirus (HPV)‐associated subsequent malignant neoplasms (SMNHPV) in childhood cancer survivors are poorly understood. Methods: The cumulative risk of SMNHPV was assessed among 24,363 Childhood Cancer Survivor Study participants. Standardized incidence ratios (SIRs) and absolute excess risk were calculated using age‐matched, sex‐matched, and calendar year rates from the Surveillance, Epidemiology, and End Results program. Poisson regression models identified SMNHPV risk factors, evaluating relative SIRs (rSIR) and 95% confidence intervals (95% CIs). Results: In total, 46 survivors developed an SMNHPV (median age, 31 years [range, 10‐56 years]; median time from primary cancer, 21 years [range, 9‐35 years]). SMNHPV sites included oropharynx (N = 44), anorectum (N = 6), uterine cervix (N = 2), and vulva (N = 2). The 33‐year cumulative incidence was 0.3% (95% CI, 0.2%‐0.4%), and the SIR was nearly 3‐fold that of the general population (SIR, 2.86; 95% CI, 2.05‐4.00). Female survivors were not at increased risk of cervical or vulvar cancers compared with the general population. All survivors had an elevated risk of oropharyngeal SMNHPV (males: SIR, 4.06; 95% CI, 2.37‐6.97; females: SIR, 8.44; 95% CI 4.88‐14.61) and anorectal SMNHPV (males: SIR, 13.56; 95% CI, 5.09‐36.13; females: SIR, 9.15; 95% CI, 2.29‐36.61). Males (vs females: rSIR, 1.99; 95% CI, 1.00‐3.94); head, neck, and pelvic radiotherapy doses >3000 centigray (vs none: rSIR, 2.35; 95% CI, 1.11‐4.97); and cisplatin‐equivalent doses >400 mg/m2 (vs none: rSIR, 4.51; 95% CI, 1.78‐11.43) were associated with increased SMNHPV SIRs in multivariable analysis. Conclusions: Childhood cancer survivors are at increased risk for SMN in sites susceptible to HPV‐associated malignancies. Further research examining HPV in the etiology of SMN and the promotion of HPV vaccination and surveillance guidelines for SMNHPV in cancer survivors is warranted. Childhood cancer survivors are at increased risk for subsequent malignant neoplasms in anatomic sites associated with human papillomavirus infection. The promotion of prevention and surveillance strategies for these subsequent malignancies is warranted in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Seizures' impact on cognition and quality of life in childhood cancer survivors.
- Author
-
Phillips, Nicholas S., Khan, Raja B., Li, Chenghong, Mirzaei Salehabadi, Sedigheh, Brinkman, Tara M., Srivastava, Deokumar, Robison, Leslie L., Hudson, Melissa M., Krull, Kevin R., and Sadighi, Zsila S.
- Subjects
- *
CHILDHOOD cancer , *CANCER survivors , *EPILEPSY , *BRAIN tumors , *COGNITIVE testing , *QUALITY of life , *SEIZURES (Medicine) , *EXECUTIVE function - Abstract
Background: The objective of this study was to determine the impact of seizure‐related factors on neurocognitive, health‐related quality of life (HRQOL), and social outcomes in survivors of childhood cancer. Methods: Survivors of childhood cancer treated at St. Jude Children's Hospital (n = 2022; 48.3% female; median age, 31.5 years; median time since diagnosis, 23.6 years) completed neurocognitive testing and questionnaires. The presence, severity, resolution, and treatment history of seizures were abstracted from medical records. Adjusting for the age at diagnosis, sex, and prior cancer therapy, multivariable models examined the impact of seizures on neurocognitive and HRQOL outcomes. Mediation analyses were conducted for social outcomes. Results: Seizures were identified in 232 survivors (11.5%; 29.9% of survivors with central nervous system [CNS] tumors and 9.0% of those without CNS tumors). In CNS tumor survivors, seizures were associated with poorer executive function and processing speed (P <.02); in non‐CNS tumor survivors, seizures were associated with worse function in every domain (P <.05). Among non‐CNS survivors, seizure severity was associated with worse processing speed (P =.023), and resolution was associated with better executive function (P =.028) and attention (P =.044). In CNS survivors, seizure resolution was associated with improved attention (P =.047) and memory (P <.02). Mediation analysis revealed that the impact of seizures on social outcomes was mediated by neurocognitive function. Conclusions: Seizures in cancer survivors adversely affect long‐term functional and psychosocial outcomes independently of cancer therapy. The resolution of seizure occurrence is associated with better outcomes. Seizure severity is associated with poorer outcomes and should be a focus of clinical management and patient education. Adult survivors of childhood cancer are at risk for poorer cognitive, health‐related quality of life, and social outcomes. Seizure frequency, independently of the underlying etiology, is associated with poorer outcomes in non–brain tumor survivors, and this implies that they may be a more vulnerable population with a lower threshold for impact from seizures of any severity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study.
- Author
-
Jefferies, John L., Mazur, Wojciech M., Howell, Carrie R., Plana, Juan C., Ness, Kirsten K., Li, Zhenghong, Joshi, Vijaya M., Green, Daniel M., Mulrooney, Daniel A., Towbin, Jeffrey A., Martinez, Hugo R., Goldberg, Jason F., Howell, Rebecca M., Srivastava, Deo Kumar, Robison, Leslie L., Hudson, Melissa M., and Armstrong, Gregory T.
- Subjects
- *
CHILDHOOD cancer , *ADULTS , *AEROBIC capacity , *CANCER survivors , *COHORT analysis , *LEFT ventricular hypertrophy - Abstract
Background: Limited data exist regarding left ventricular remodeling patterns observed in adult survivors of childhood cancer after therapy. Methods: Among 1190 adult survivors diagnosed with childhood cancer (median age at diagnosis, 9 years [interquartile range (IQR), 3.8‐14.4 years]; age at evaluation, 35.6 years [IQR, 29.5‐42.8 years]), treatment exposures included anthracyclines (n = 346), chest radiotherapy (n = 174), both (n = 245), or neither (n = 425). Prospective echocardiographic assessment compared survivors with 449 noncancer controls classified according to left ventricle geometric patterns. Associations between left ventricle geometric patterns and decreased exercise tolerance were assessed. Results: Overall, 28.2% of survivors (95% confidence interval [CI], 25.6%‐30.8%) exhibited concentric remodeling, 2.4% (95% CI, 1.6%‐3.5%) exhibited eccentric hypertrophy, and 1.1% (95% CI, 0.6%‐1.9%) exhibited concentric hypertrophy. A greater proportion of survivors who received only chest radiotherapy (41%) had concentric remodeling compared with those who received only anthracyclines (24%), both (27%), or neither (27%; all P <.001), and all were greater than the proportions in noncancer controls (18%; all P <.05). Concentric remodeling was associated with radiation exposure, but not with anthracycline exposure, in multivariable models. Survivors who had concentric remodeling were more likely to have a maximal oxygen uptake peak <85% compared with those who had normal geometry (81.0% vs 66.3%; odds ratio, 1.75; 95% CI, 1.15‐2.68). Conclusions: Chest radiation therapy, but not anthracycline therapy, increased the risk for concentric remodeling in survivors of childhood cancer. The presence of concentric remodeling was associated with increased exercise intolerance. Chest radiation therapy increases the risk of concentric left ventricular remodeling as assessed by echocardiography, but anthracycline therapy does not increase the risk of concentric remodeling. Adult survivors of childhood cancer who have concentric remodeling are more likely to have a relative peak oxygen uptake <85% compared with survivors who have normal left ventricular geometry. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer.
- Author
-
McCastlain, Kelly, Howell, Carrie R, Welsh, Catherine E, Wang, Zhaoming, Wilson, Carmen L, Mulder, Heather L, Easton, John, Mertens, Ann C, Zhang, Jinghui, Yasui, Yutaka, Hudson, Melissa M, Robison, Leslie L, Kundu, Mondira, and Ness, Kirsten K
- Subjects
- *
SARCOPENIA , *CHILDHOOD cancer , *MUSCLE mass , *CANCER survivors , *MUSCLE weakness , *RESEARCH , *GENETICS , *CROSS-sectional method , *RESEARCH methodology , *EVALUATION research , *MITOCHONDRIA , *COMPARATIVE studies , *RESEARCH funding , *TUMORS ,CENTRAL nervous system tumors - Abstract
Background: Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and sarcopenia among survivors.Methods: Among 1762 adult childhood cancer survivors (51.6% male; median age = 29.4 years, interquartile range [IQR] = 23.3-36.8), with a median of 20.6 years from diagnosis (IQR = 15.2-28.2), mtDNAcn estimates were derived from whole-genome sequencing. A subset was validated by quantitative polymerase chain reaction and evaluated cross-sectionally using multivariable logistic regression for their association with sarcopenia, defined by race-, age-, and sex-specific low lean muscle mass or weak grip strength. All statistical tests were 2-sided.Results: The prevalence of sarcopenia was 27.0%, higher among female than male survivors (31.5% vs 22.9%; P < .001) and associated with age at diagnosis; 51.7% of survivors with sarcopenia were diagnosed ages 4-13 years (P = .01). Sarcopenia was most prevalent (39.0%) among central nervous system tumor survivors. Cranial radiation (odds ratio [OR] = 1.84, 95% confidence interval [CI] = 1.32 to 2.59) and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased, whereas glucocorticoids decreased odds (OR = 0.72, 95% CI = 0.56 to 0.93) of sarcopenia. mtDNAcn decreased with age (β = -0.81, P = .002) and was higher among female survivors (β = 9.23, P = .01) and among survivors with a C allele at mt.204 (β = -17.9, P = .02). In adjusted models, every standard deviation decrease in mtDNAcn increased the odds of sarcopenia 20% (OR = 1.20, 95% CI = 1.07 to 1.34).Conclusions: A growing body of evidence supports peripheral blood mtDNAcn as a biomarker for adverse health outcomes; however, this study is the first to report an association between mtDNAcn and sarcopenia among childhood cancer survivors. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. Clinical and genetic risk factors for radiation‐associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
- Author
-
Trendowski, Matthew R., Baedke, Jessica L., Sapkota, Yadav, Travis, Lois B., Zhang, Xindi, El Charif, Omar, Wheeler, Heather E., Leisenring, Wendy M., Robison, Leslie L., Hudson, Melissa M., Morton, Lindsay M., Oeffinger, Kevin C., Howell, Rebecca M., Armstrong, Gregory T., Bhatia, Smita, and Dolan, M. Eileen
- Subjects
- *
TINNITUS , *VERTIGO , *MEDICAL personnel , *GENOME-wide association studies , *CHILDHOOD cancer , *CANCER survivors , *OTOTOXICITY , *GERIATRIC oncology , *RADIOTHERAPY safety - Abstract
BACKGROUND: Cranial radiation therapy (CRT) is associated with ototoxicity, which manifests as hearing loss and tinnitus. The authors sought to identify clinical determinants and genetic risk factors for ototoxicity among adult survivors of pediatric cancer treated with CRT. METHODS: Logistic regression evaluated associations of tinnitus (n = 1991) and hearing loss (n = 2198) with nongenetic risk factors and comorbidities among CRT‐treated survivors in the Childhood Cancer Survivor Study. Genome‐wide association studies (GWASs) of CRT‐related tinnitus and hearing loss were also performed. RESULTS: Males were more likely to report CRT‐related tinnitus (9.4% vs 5.4%; P = 5.1 × 10−4) and hearing loss (14.0% vs 10.7%; P =.02) than females. Survivors with tinnitus or hearing loss were more likely to experience persistent dizziness or vertigo (tinnitus: P < 2 × 10−16; hearing loss: P = 6.4 × 10−9), take antidepressants (tinnitus: P =.02; hearing loss: P =.01), and report poorer overall health (tinnitus: P = 1.5 × 10−6; hearing loss: P = 1.7 × 10−6) in comparison with controls. GWAS of CRT‐related tinnitus revealed a genome‐wide significant signal in chromosome 1 led by rs203248 (P = 1.5 × 10−9), whereas GWAS of CRT‐related hearing loss identified rs332013 (P = 5.8 × 10−7) in chromosome 8 and rs67522722 (P = 7.8 × 10−7) in chromosome 6 as nearly genome‐wide significant. A replication analysis identified rs67522722, intronic to ATXN1, as being significantly associated with CRT‐related hearing loss (P =.03) and de novo hearing loss (P = 3.6 × 10−4). CONCLUSIONS: CRT‐associated ototoxicity was associated with sex, several neuro‐otological symptoms, increased antidepressant use, and poorer self‐reported health. GWAS of CRT‐related hearing loss identified rs67522722, which was supported in an independent cohort of survivors. LAY SUMMARY: Hearing loss and subjective tinnitus (the perception of noise or ringing in the ear) are long‐term side effects of cancer treatment and are common in children treated with radiation to the brain.These toxicities can affect childhood development and potentially contribute to serious learning and behavioral difficulties.This study's data indicate that males are at greater risk for hearing loss and tinnitus than females after radiation therapy to the brain.Those who develop these toxicities are more likely to use antidepressants and report poorer overall health.Health care providers can improve the management of survivors by informing patients and/or their parents of these risks. Health care providers can improve the management of survivors of childhood cancer by informing patients of ototoxicity risk and associated comorbidities (dizziness and vertigo) after the completion of cranial radiation therapy. Genome‐wide association studies reveal genetic variants in ATXN1, a gene associated with spinocerebellar ataxia type 1, to be significantly associated with cranial radiation therapy–related hearing loss. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: A Children's Oncology Group Study
- Author
-
Zierhut, Heather, Linet, Martha S., Robison, Leslie L., Severson, Richard K., and Spector, Logan
- Subjects
- *
LYMPHOBLASTIC leukemia in children , *CANCER , *FAMILY history (Medicine) , *TUMORS in children , *GROUP work in research , *CANCER research , *HISTORY , *CANCER risk factors - Abstract
Abstract: Background: Studies of family history of cancer and non-malignant diseases in childhood acute lymphoblastic leukemia (ALL) show inconsistent findings. Most studies show no increased risk with family history of cancer. Non-malignant diseases such as allergic diseases, autoimmune diseases, birth defects and thyroid diseases have been reported to be associated with ALL. Methods: We conducted a case-control study of family history of cancer and selected non-malignant conditions (allergic diseases, autoimmune diseases, birth defects, and thyroid diseases). ALL cases were obtained from Children''s Cancer Group institutions from January 1989 to June 1993. Controls were recruited via random digit dialing. Family history for first degree relatives and grandparents of ALL cases and controls was collected by structured telephone questionnaires. Conditional logistical regression was used to calculate odds ratios adjusting for potential confounders. Results: We found a borderline association of ALL and having a family member with a history of cancer in cases (n =1842) compared to controls (n =1986) (OR=0.98, 95%CI=0.93, 1.00) and an inverse association for esophageal cancer based on small numbers. Family history of food and drug allergies demonstrated a modestly reduced risk (OR=0.83, 95%CI=0.73, 0.95) as did family history of rheumatoid arthritis (OR=0.79, 95%CI=0.65, 0.96). There were no associations with family history of any autoimmune diseases, immunodeficiencies, birth defects, thyroid diseases and risk of childhood ALL. Conclusions: These results show no association of overall family history of cancer with childhood ALL, while providing additional evidence for an inverse association with family history of allergic disease. Two potentially new associations of ALL with family history of esophageal cancer and rheumatoid arthritis require confirmation in other studies and validation with medical records. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
49. Comparability and Representativeness of Control Groups in a Case-Control Study of Infant Leukemia: A Report From the Children's Oncology Group.
- Author
-
Puumala, Susan E., Spector, Logan G., Robison, Leslie L., Bunin, Greta R., Olshan, Andrew F., Linabery, Amy M., Roesler, Michelle A., Blair, Cindy K., and Ross, Julie A.
- Subjects
- *
LEUKEMIA in children , *CHILDHOOD cancer , *PEDIATRICS , *PREGNANCY , *MOTHERS - Abstract
Traditionally, controls in US pediatric cancer studies were selected through random digit dialing. With declining participation and lack of nonparticipant information, random digit dialing (RDD) controls may be substandard. Birth certificate (BC) controls are an alternative, because they are population based and include data from nonparticipants. The authors examined controls collected by random digit dialing and birth certificates for a Children's Oncology Group case-control study of infant leukemia in 1995–2006. Demographic variables were used to assess differences in RDD and BC controls and their representativeness. RDD and BC controls did not differ significantly with regard to maternal variables (age, race, education, marital status, alcohol during pregnancy) or child variables (sex, gestational age, birth weight), but they varied in smoking during pregnancy (22% RDD controls, 12% BC controls) (P = 0.05). The study's combined control group differed significantly from US births: Mothers of controls were more likely to be older (29.8 vs. 27.2 years), white (84% vs. 59%), and married (85% vs. 67%) and to have >16 years of education (37% vs. 25%). Control children were more often full term (88% vs. 81%) and heavier (3,436 vs. 3,317 g). Finally, participating BC mothers were likely to be older and to have more education than nonparticipants. Thus, the study's control groups were comparable but differed from the population of interest. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
50. Progression of Frailty in Survivors of Childhood Cancer: A St. Jude Lifetime Cohort Report.
- Author
-
Delaney, Angela, Howell, Carrie R, Krull, Kevin R, Brinkman, Tara M, Armstrong, Gregory T, Chemaitilly, Wassim, Wilson, Carmen L, Mulrooney, Daniel A, Wang, Zhaoming, Lanctot, Jennifer Q, Johnson, Ruth E, Krull, Matthew R, Partin, Robyn E, Shelton, Kyla C, Srivastava, Deo Kumar, Robison, Leslie L, Hudson, Melissa M, and Ness, Kirsten K
- Subjects
- *
FRAILTY , *CHILDHOOD cancer , *CANCER survivors , *STRENGTH training , *AGE - Abstract
Background: Some adult survivors of childhood cancers develop frailty at higher rates than expected based on their chronological age. This study examined the incidence of frailty among survivors at 10 or more years after diagnosis, frailty prevalence 5 years later, and risk factors for becoming frail.Methods: Frailty was measured at study entry and 5 years later. Logistic regression tested the associations of several factors with having frailty at 5 years for all participants and separately by sex and by study entry frailty status. Cox models evaluated the hazard of death associated with entry frailty considering covariates.Results: Cancer survivors (range = 0-22 years at diagnosis, median = 7 years) were ages 18-45 years (median = 30 years) at study entry. Frailty prevalence increased from 6.2% (95% confidence interval [CI] = 5.0% to 7.5%) to 13.6% (95% CI = 11.9% to 15.4%) at 5 years. Risk factors for frailty at follow-up among all survivors included chest radiation 20 Gy or higher (odds ratio [OR] = 1.98, 95% CI = 1.29 to 3.05), cardiac (OR = 1.58, 95% CI = 1.02 to 2.46), and neurological (OR = 2.58, 95% CI = 1.69 to 3.92) conditions; lack of strength training (OR = 1.74, 95% CI = 1.14 to 2.66); sedentary lifestyle (OR = 1.75, 95% CI = 1.18 to 2.59); and frailty at study entry (OR = 11.12, 95% CI = 6.64 to 18.61). The strongest risk factor for death during follow-up was prior frailty (OR = 3.52, 95% CI = 1.95 to 6.32).Conclusions: Prevalent frailty more than doubled at 5 years after study entry among adult childhood cancer survivors. Frailty at entry was the strongest risk factor for death. Because treatment exposures cannot be changed, mitigation of other risk factors for frailty, including lack of strength training and sedentary lifestyle, may decrease risk of adverse health events and improve longevity in survivors. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.